{"content":"<li class=\"n-box-item date-title\" data-end=\"1523937599\" data-start=\"1523851200\" data-txt=\"Monday, December 23, 2019\">Monday, April 16, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3345988\" data-ts=\"1523920626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PUMP\" target=\"_blank\">PUMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345988-five-below-propetro-changing-indexes-in-s-and-p-moves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below, ProPetro changing indexes in S&amp;P moves</a></h4><ul>   <li>ProPetro (NYSE:<a href='https://seekingalpha.com/symbol/PUMP' title='ProPetro'>PUMP</a>) is <font color='green'>up 6.3%</font> after hours following news that it's <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/693751_pump4five6dstssc.pdf?force_download=true\" target=\"_blank\">joining the S&amp;P SmallCap 600</a>.</li>    <li>The company will replace Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>), which is heading into the S&amp;P MidCap 400. Five Below is <font color='green'>up 0.6%</font> after hours.</li>    <li>Up in the MidCap 400, Five Below is replacing DST Systems (NYSE:<a href='https://seekingalpha.com/symbol/DST' title='DST Systems Inc.'>DST</a>), set to be acquired by SS&amp;C Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SSNC' title='SS&C Technologies Holdings, Inc.'>SSNC</a>) tomorrow.</li>    <li>The index moves are effective prior to the open on Thursday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345988\" data-linked=\"Five Below, ProPetro changing indexes in S&amp;P moves\" data-tweet=\"$PUMP $PUMP $FIVE - Five Below, ProPetro changing indexes in S&amp;P moves https://seekingalpha.com/news/3345988-five-below-propetro-changing-indexes-in-s-and-p-moves?source=tweet\" data-url=\"https://seekingalpha.com/news/3345988-five-below-propetro-changing-indexes-in-s-and-p-moves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345986\" data-ts=\"1523920031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345986-bellicum-pharmaceuticalsminus-6_9-on-7m-share-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellicum Pharmaceuticals -6.9% on 7M-share public offering</a></h4><ul>   <li>Bellicum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a>) -- a <a href=\"https://seekingalpha.com/news/3345124-bellicum-plus-18_3-percent-fda-lifts-clinical-hold-bpxminus-501-studies\" target=\"_blank\">big gainer last Wednesday</a> as the FDA lifted a clinical hold -- is <font color='red'>6.9% lower</font> in postmarket action after announcing a <a href=\"https://seekingalpha.com/pr/17130914-bellicum-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">7M-share public offering</a>.</li>    <li>Citigroup and Jefferies are lead book-running managers.</li>    <li>Bellicum expects to grant a 30-day option to buy up to an additional 1,050,000 shares of common stock at the offering price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345986\" data-linked=\"Bellicum Pharmaceuticals -6.9% on 7M-share public offering\" data-tweet=\"$BLCM - Bellicum Pharmaceuticals -6.9% on 7M-share public offering https://seekingalpha.com/news/3345986-bellicum-pharmaceuticalsminus-6_9-on-7m-share-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3345986-bellicum-pharmaceuticalsminus-6_9-on-7m-share-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345976\" data-ts=\"1523915122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345976-lululemon-names-vf-corp-s-guido-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon names VF Corp.&#39;s Guido as new CFO</a></h4><ul>     <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) <font color='green'>+2.2%</font> after-hours on news it hired Patrick Guido as its <a href=\"https://seekingalpha.com/pr/17130888-lululemon-athletica-names-patrick-guido-chief-financial-officer\" target=\"_blank\">new CFO</a>, effective April 30, even as the company continues to search for a new CEO.</li>     <li>Guido boasts more than 15 years' experience at top retail companies, including the past seven years at VF Corp., where he served as Treasurer and VP of Corporate Development.</li>     <li>LULU says Guido will report to COO Stuart Haselden.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345976\" data-linked=\"Lululemon names VF Corp.&#39;s Guido as new CFO\" data-tweet=\"$LULU - Lululemon names VF Corp.&#39;s Guido as new CFO https://seekingalpha.com/news/3345976-lululemon-names-vf-corp-s-guido-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3345976-lululemon-names-vf-corp-s-guido-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345973\" data-ts=\"1523914542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345973-after-hours-gainers-losers-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (04/16/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a> <font color='green'>+5.7%</font>. <a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>&nbsp;<font color='green'>+5.5%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>&nbsp;<font color='green'>+4.1%</font>. <a href='https://seekingalpha.com/symbol/NOV' title='National Oilwell Varco, Inc.'>NOV</a>&nbsp;<font color='green'>+2.6%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a> <font color='red'>-7.8%</font>. <a href='https://seekingalpha.com/symbol/FND' title='Floor & Decor Holdings, Inc.'>FND</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/PINC' title='Premier, Inc.'>PINC</a>&nbsp;<font color='red'>-1.9%.&nbsp;</font><a href='https://seekingalpha.com/symbol/WES' title='Western Gas Partners, L.P.'>WES</a>&nbsp;<font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/AMGP' title='Antero Midstream GP LP'>AMGP</a>&nbsp;<font color='red'>-1.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345973\" data-linked=\"After Hours Gainers / Losers (04/16/2018)\" data-tweet=\"$NFLX $NFLX $CE - After Hours Gainers / Losers (04/16/2018) https://seekingalpha.com/news/3345973-after-hours-gainers-losers-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345973-after-hours-gainers-losers-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345964\" data-ts=\"1523912288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAC\" target=\"_blank\">SEAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345964-seachangeminus-8_1-quarterly-report-provides-dim-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaChange -8.1% as quarterly report provides dim guidance</a></h4><ul>   <li>SeaChange (NASDAQ:<a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a>) is <font color='red'>8.1% lower</font> after hours after its <a href=\"https://seekingalpha.com/news/3345935-seachange-beats-revenue\" target=\"_blank\">Q4 earnings</a> beat slightly but contained downbeat guidance for the current quarter.</li>    <li>Revenues dipped overall as services lagged product sales.</li>    <li>The Q4 results included non-GAAP charges of $2.1M, with severance and restructuring costs making up $1.1M of that. The prior year's quarter had $22.3M of non-GAAP charges.</li>    <li>\"The fourth quarter marks our second consecutive quarter of operating profitability, evidence that our initiatives to reduce costs and return the Company to profitability and positive cash flow have taken hold,\" says CFO Peter Faubert.</li>    <li>Revenue breakout: Products, $9.88M (up 27.9%); Services, $13.1M (down 18.8%).</li>    <li>It's guiding to Q1 revenue of $13M-$15M, light of consensus for $18.6M, with a non-GAAP loss of $0.15 to $0.11 per share (below expectations for a loss of $0.01/share).</li>    <li>For the full year, it sees revenue of $80M-$90M (vs. consensus for $83.8M) and non-GAAP operating income of $0.10-$0.25 (vs. expected $0.15).</li>    <li>Cash, equivalents, restricted cash and marketable securities were $52M against no debt as of Jan. 31.</li>    <li><a href=\"http://www.schange.com/IR\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17130778-seachange-international-reports-fourth-quarter-full-year-fiscal-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3345964\" data-linked=\"SeaChange -8.1% as quarterly report provides dim guidance\" data-tweet=\"$SEAC - SeaChange -8.1% as quarterly report provides dim guidance https://seekingalpha.com/news/3345964-seachangeminus-8_1-quarterly-report-provides-dim-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3345964-seachangeminus-8_1-quarterly-report-provides-dim-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345955\" data-ts=\"1523911160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRSP\" target=\"_blank\">CRSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345955-preclinical-data-show-potential-effectiveness-of-crispr-therapeutics-off-shelf-car-t-cells\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Preclinical data show potential effectiveness of CRISPR Therapeutics&#39; off-the-shelf CAR-T cells; shares up 2% after hours</a></h4><ul><li>Gene editor CRISPR Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;after hours on modest volume on the heels of its <a href=\"https://seekingalpha.com/pr/17130767-crispr-therapeutics-presents-positive-data-allogeneic-crispr-based-car-t-cell-therapies-aacr\" target=\"_blank\">announcement </a>of encouraging preclinical data supporting the potential efficacy of its off-the-shelf CAR-T candidates. The results were presented at the American Association for Cancer Research Annual Meeting in Chicago.</li><li>The data, supporting the work already done on lead allogeneic candidate CTX101, showed allogeneic CAR-T cells targeting B cell maturation antigen &#40;BCMA&#41; generated with CRISPR/Cas9 as a potential approach to treating multiple myeloma &#40;MM&#41; selectively killed BCMA+ cells <em>in vitro</em> and eradicated MM cells in<em> in vitro</em> and <em>in vivo</em> models.</li><li>Using CRISPR/Cas9, allogeneic CAR-T cells targeting the CD70 antigen, a key target in blood cancers and certain solid tumors, showed effectiveness in killing cancer cells in lymphoid and renal cancer cell lines. The CD70-targeting CAR-T cells eradicated renal cell carcinoma cells in an <em>in vivo</em> mouse model.</li><li>CEO Samarth Kulkarni says the company's first IND should be filed by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345955\" data-linked=\"Preclinical data show potential effectiveness of CRISPR Therapeutics&#39; off-the-shelf CAR-T cells; shares up 2% after hours\" data-tweet=\"$CRSP - Preclinical data show potential effectiveness of CRISPR Therapeutics&#39; off-the-shelf CAR-T cells; shares up 2% after hours https://seekingalpha.com/news/3345955-preclinical-data-show-potential-effectiveness-of-crispr-therapeutics-off-shelf-car-t-cells?source=tweet\" data-url=\"https://seekingalpha.com/news/3345955-preclinical-data-show-potential-effectiveness-of-crispr-therapeutics-off-shelf-car-t-cells\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345948\" data-ts=\"1523910599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CE\" target=\"_blank\">CE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345948-celanese-beats-0_43-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celanese beats by $0.43, beats on revenue</a></h4><ul><li>Celanese (NYSE:<a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a>): Q1 EPS of $2.79 <font color='green'>beats by $0.43</font>.</li><li>Revenue of $1.85B (+25.9% Y/Y) <font color='green'>beats by $150M</font>.</li><li>Shares <font color='green'>+3.47%</font>.</li><li><a href='https://seekingalpha.com/pr/17130871-celanese-corporation-reports-first-quarter-2018-earnings-increases-2018-outlook'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3345948\" data-linked=\"Celanese beats by $0.43, beats on revenue\" data-tweet=\"$CE - Celanese beats by $0.43, beats on revenue https://seekingalpha.com/news/3345948-celanese-beats-0_43-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3345948-celanese-beats-0_43-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345945\" data-ts=\"1523910084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345945-netflix-smashes-subscriber-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix smashes subscriber estimates</a></h4><ul>     <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) jumps in AH trading after posting Q1 subscriber numbers above estimates.</li>     <li>The company reported 1.96M domestic streaming additions vs. 1.48M consensus and guidance for 1.45M guidance.</li>     <li>International streaming additions rose to 5.46M during the quarter vs. 4.98M consensus and guidance for 4.90M</li>     <li>Total streamings adds were 7.41M for the quarter vs. 6.32M consensus. Total memberships were 125M at the end of the quarter.</li>     <li>Q1 U.S. streaming contribution margin increased to 38.3% from 34.4% last quarter. The international contribution margin rate was 15.3%.</li>     <li>The company's operating margin jumped to 12.1% from 7.5% in Q4.</li>     <li>Netflix on cash and debt: \"We have about $2.6 billion in cash and we will continue to raise debt as needed to fund our increase in original content. Our debt levels are quite modest as a percentage of our enterprise value, and we believe the debt is lower cost of capital compared to equity.\"</li>     <li>Netflix on content spending: \"We&rsquo;ll have $7.5-$8 billion of content expense (on a P&amp;L basis) in 2018 across a wide variety of formats (series, films, unscripted, docs, comedy specials, non-English language) to serve the diverse tastes of our growing global membership base.\"</li>     <li>Looking ahead, Netflix expects Q2 total streaming adds of 6.20M vs. 6.30M consensus.</li>     <li>Source: <a href=\"https://ir.netflix.com/investor-events\" target=\"_blank\">Netflix Q1 shareholder letter</a></li>     <li>Upcoming: <a href=\"https://ir.netflix.com/investor-events\" target=\"_blank\">Netflix earnings call webcast</a></li>     <li>NFLX <font color='green'>+6.34%</font> AH to $327.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345945\" data-linked=\"Netflix smashes subscriber estimates\" data-tweet=\"$NFLX - Netflix smashes subscriber estimates https://seekingalpha.com/news/3345945-netflix-smashes-subscriber-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3345945-netflix-smashes-subscriber-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>185&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345942\" data-ts=\"1523909951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345942-rokuplus-6-on-espn-plus-availability-point72-notes-5-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +6% on ESPN Plus availability; Point72 notes 5% stake</a></h4><ul>     <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color='green'>up 6%</font> after hours following a post-close notice that it's <a href=\"https://seekingalpha.com/pr/17130769-espn-direct-consumer-subscription-streaming-service-now-available-roku-devices\" target=\"_blank\">making available</a> new streaming service ESPN Plus (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) on its players.</li>     <li>It's newly updated its ESPN channel to make the new service available for those subscribers paying ESPN the $4.99/month.</li>     <li>The service is accessible to anything with a current-gen device, Roku says.</li>   <li><b>Updated 4:36 p.m.:</b> In a 13G filing after the close, Steve Cohen's Point72 Asset Management <a href=\"https://seekingalpha.com/filing/3977327\" target=\"_blank\">reported a 5.1% stake</a> in Roku; the filing of a 13G indicates a passive stake rather than an active one.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345942\" data-linked=\"Roku +6% on ESPN Plus availability; Point72 notes 5% stake\" data-tweet=\"$ROKU $ROKU $DIS - Roku +6% on ESPN Plus availability; Point72 notes 5% stake https://seekingalpha.com/news/3345942-rokuplus-6-on-espn-plus-availability-point72-notes-5-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3345942-rokuplus-6-on-espn-plus-availability-point72-notes-5-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345941\" data-ts=\"1523909808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345941-netflix-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix beats by $0.01, beats on revenue</a></h4><ul><li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>): Q1 EPS of $0.64 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $3.7B (+40.2% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+6%</font>.</li><li><a href=\"https://ir.netflix.com/static-files/419958ac-5fd7-4bcd-9fb1-ebca445a9016\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3345941\" data-linked=\"Netflix beats by $0.01, beats on revenue\" data-tweet=\"$NFLX - Netflix beats by $0.01, beats on revenue https://seekingalpha.com/news/3345941-netflix-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3345941-netflix-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345940\" data-ts=\"1523909804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTSI\" target=\"_blank\">MTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345940-macom-says-zte-sales-immaterial-to-q2-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MACOM says ZTE sales were &quot;immaterial&quot; to Q2 revenue</a></h4><ul><li>        MACOM (NASDAQ:<a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a>)<a href=\"https://seekingalpha.com/pr/17130795-macom-comments-news-u-s-department-commerce-ban-exports-zte\" target=\"_blank\"> comments</a> on the U.S. Department of Commerce export ban to ZTE.</li><li>               MACOM says that sales to ZTE in the most recently completed second quarter totaled $1.6M and was immaterial to the revenue as a whole.&nbsp;</li><li>               MACOM shares closed today&nbsp;<font color='red'>down 9.2%</font>&nbsp;but are&nbsp;<font color='green'>up 1.3%&nbsp;</font>aftermarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345789-optical-networkers-slide-amid-ban-selling-zte\" target=\"_blank\">Optical networkers slide amid ban on selling to ZTE</a> (April 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345880-jpmorgan-defends-inphi-zte-related-weakness\" target=\"_blank\">JPMorgan defends Inphi on ZTE-related weakness</a> (April 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345926-winners-losers-among-opticals-u-s-ban-zte-sales\" target=\"_blank\">Winners and losers among opticals from U.S. ban on ZTE sales</a> (April 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345940\" data-linked=\"MACOM says ZTE sales were &quot;immaterial&quot; to Q2 revenue\" data-tweet=\"$MTSI - MACOM says ZTE sales were &quot;immaterial&quot; to Q2 revenue https://seekingalpha.com/news/3345940-macom-says-zte-sales-immaterial-to-q2-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3345940-macom-says-zte-sales-immaterial-to-q2-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345927\" data-ts=\"1523908616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGA\" target=\"_blank\">TGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345927-transglobe-energy-to-seek-listing-on-london-stock-exchanges-aim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransGlobe Energy to seek listing on London Stock Exchange&#39;s AIM</a></h4><ul>     <li>TransGlobe Energy (<a href='https://seekingalpha.com/symbol/TGA' title='Transglobe Energy Corp'>TGA</a> <font color='green'>+2.9%</font>) moves higher after providing an <a href=\"https://seekingalpha.com/pr/17129611-transglobe-energy-corporation-announces-operations-update-intention-list-aim-pending-board\" target=\"_blank\">operations update</a> and saying it plans to list on the London Stock Exchange&rsquo;s AIM market.</li>     <li>TGA says its Q1 production was on plan, averaging 14,366 boe/day, and its 2018 Canadian drilling program is targeting to begin drilling as many as eight (six  net) Cardium wells in July, which could include a two-mile  horizontal well to evaluate extended reach horizontals in the Harmattan area.</li>     <li>Also, TGA believes a listing on London&rsquo;s AIM market will provide access to a significant pool of specialist investors who currently do not have adequate access to the stock; it plans to establish an executive office in London by this September.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345927\" data-linked=\"TransGlobe Energy to seek listing on London Stock Exchange&#39;s AIM\" data-tweet=\"$TGA - TransGlobe Energy to seek listing on London Stock Exchange&#39;s AIM https://seekingalpha.com/news/3345927-transglobe-energy-to-seek-listing-on-london-stock-exchanges-aim?source=tweet\" data-url=\"https://seekingalpha.com/news/3345927-transglobe-energy-to-seek-listing-on-london-stock-exchanges-aim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345926\" data-ts=\"1523908579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCLR\" target=\"_blank\">OCLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345926-winners-and-losers-among-opticals-from-u-s-ban-on-zte-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Winners and losers among opticals from U.S. ban on ZTE sales</a></h4><ul>   <li>In a reaction to the Commerce Dept. <a href=\"https://seekingalpha.com/news/3345789-optical-networkers-slide-amid-ban-selling-zte\" target=\"_blank\">banning sales and exports</a> to Chinese equipment maker ZTE (<a href=\"http://seekingalpha.com/symbol/ZTCOF\" target=\"_blank\">ZTCOF</a> <font color='red'>-13.8%</font>), Acacia Networks (<a href=\"http://seekingalpha.com/symbol/ACIA\" target=\"_blank\">ACIA</a> <font color='red'>-35.5%</font>) says it's <a href=\"https://seekingalpha.com/pr/17130719-acacia-communications-provides-update-u-s-department-commerce-zte-statement\" target=\"_blank\">aware of the move and acting</a>.</li>    <li>\"Acacia is taking steps to suspend affected transactions and is assessing the impact of these developments on Acacia,\" the company says.</li>    <li>Shares have tumbled today in the wake of the DOC move, and Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>) is <font color='red'>down 14.9%</font>. Other optical names are less affected but still down in an up market: <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='red'>-3.8%</font>; <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-3.4%</font>; II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) <font color='red'>-4%</font>; <a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a> <font color='red'>-2.6%</font>; <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-1.3%</font>.</li>    <li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) and Nokia (<a href=\"http://seekingalpha.com/symbol/NOK\" target=\"_blank\">NOK</a> <font color='green'>+1.7%</font>) should benefit from the ban, says MKM, due to less exposure. Huawei and Nokia will pick up market share in 100+G optical systems since ZTE won't be able to get cutting-edge components, and Lumentum (<a href=\"http://seekingalpha.com/symbol/LITE\" target=\"_blank\">LITE</a> <font color='red'>-8.9%</font>) is showing a buying opportunity with little ZTE exposure as well. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345926\" data-linked=\"Winners and losers among opticals from U.S. ban on ZTE sales\" data-tweet=\"$OCLR $OCLR $FNSR - Winners and losers among opticals from U.S. ban on ZTE sales https://seekingalpha.com/news/3345926-winners-and-losers-among-opticals-from-u-s-ban-on-zte-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3345926-winners-and-losers-among-opticals-from-u-s-ban-on-zte-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345922\" data-ts=\"1523907618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345922-dynavax-techs-lead-candidate-combined-keytruda-shows-positive-action-in-early-stage-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynavax Tech&#39;s lead candidate combined with Keytruda shows positive action in early-stage studies</a></h4><ul><li>Dynavax Technologies' (<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='red'>-6.8%</font>) lead candidate SD-101, combined with Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+2.6%</font>) KEYTRUDA (pembrolizumab), showed <a href=\"https://seekingalpha.com/pr/17130653-dynavax-reports-interim-data-sdminus-101-combination-keytruda-pembrolizumab-patients-advanced\" target=\"_blank\">positive effects</a> in early-stage studies in head-and-neck cancer and melanoma. The data are being presented at the American Association for Cancer Research Annual Meeting in Chicago.</li><li>Preliminary results from a Phase 1b/2 study in patients with advanced head-and-neck squamous cell carcinoma showed showed an objective response rate &#40;ORR&#41; of 33% (n=6/18) with no dose-limiting toxicities.</li><li>Preliminary data from a Phase 1b/2 study in advanced melanoma showed that 86% of the initial responses were sustained after a median of 18 months (n=6/7) in patients not previously treated with a PD-1 inhibitor. 17% (n=2/12) of evaluable patients who progressed on prior anti-PD-1 therapy achieved partial or stable disease for at least 10.5 months. Median progression-free survival &#40;PFS&#41;, duration of response and median overall survival &#40;OS&#41; have not been reached.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271405-combination-dynavaxs-sdminus-101-keytruda-show-100-percent-response-melanoma-study-shares\" target=\"_blank\">Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours</a> (June 2, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345922\" data-linked=\"Dynavax Tech&#39;s lead candidate combined with Keytruda shows positive action in early-stage studies\" data-tweet=\"$DVAX $DVAX $MRK - Dynavax Tech&#39;s lead candidate combined with Keytruda shows positive action in early-stage studies https://seekingalpha.com/news/3345922-dynavax-techs-lead-candidate-combined-keytruda-shows-positive-action-in-early-stage-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3345922-dynavax-techs-lead-candidate-combined-keytruda-shows-positive-action-in-early-stage-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345920\" data-ts=\"1523907069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPD\" target=\"_blank\">EPD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345920-enterprise-products-starts-full-service-on-expanded-midland-to-sealy-pipeline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enterprise Products starts full service on expanded Midland-to-Sealy pipeline</a></h4><ul>     <li>Enterprise Products Partners (<a href='https://seekingalpha.com/symbol/EPD' title='Enterprise Products Partners L.P'>EPD</a> <font color='green'>+4.2%</font>) says its expanded 416-mile Midland-to-Sealy pipeline has <a href=\"https://seekingalpha.com/pr/17129895-enterprise-begins-full-service-midland-sealy-pipeline\" target=\"_blank\">started full service</a> with an expanded capacity of 540K bbl/day.</li><li>EPD says a further expansion of the pipeline next month will increase capacity to 575K bbl/day with the completion of incremental tankage and infrastructure and  operating enhancements, and is fully subscribed under  long-term contracts.</li><li>The line has capacity to move four grades of crude - West Texas  Intermediate, light West Texas Intermediate, West Texas Sour and condensate.</li><li>Volumes on the Midland-to-Sealy pipeline <a href=\"http://www.argusmedia.com/news/article/?id=1662828\" target=\"_blank\">averaged 333K bbl/day during Q4</a> 2017 since it began limited service in November.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345920\" data-linked=\"Enterprise Products starts full service on expanded Midland-to-Sealy pipeline\" data-tweet=\"$EPD - Enterprise Products starts full service on expanded Midland-to-Sealy pipeline https://seekingalpha.com/news/3345920-enterprise-products-starts-full-service-on-expanded-midland-to-sealy-pipeline?source=tweet\" data-url=\"https://seekingalpha.com/news/3345920-enterprise-products-starts-full-service-on-expanded-midland-to-sealy-pipeline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345918\" data-ts=\"1523906853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345918-reuters-google-will-resume-drug-treatment-ads-verification\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Google will resume drug treatment ads with verification</a></h4><ul><li>        <a href=\"https://www.reuters.com/article/us-alphabet-google-ads-exclusive/exclusive-google-unveils-vetting-process-for-drug-rehab-ads-idUSKBN1HN28X?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">Reuters reports</a> that nearly a year after suspending the practice, Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) will resume running ads from U.S. addiction treatment centers starting in July.</li><li>               Alphabet had ended the practice last September due to a high number of deceptive ads. Kantar Media predicts the ban cut off $78M of annual ad revenue from the U.S. alone.&nbsp;</li><li>               Treatment centers wanting to run an ad will have to be vetted by LegitScript, which will check the providers for 15 criteria, which includes background checks and licensing verification.&nbsp;</li><li>Alphabet shares are&nbsp;<font color='green'>up 0.9%</font>.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345918\" data-linked=\"Reuters: Google will resume drug treatment ads with verification\" data-tweet=\"$GOOG $GOOG $GOOGL - Reuters: Google will resume drug treatment ads with verification https://seekingalpha.com/news/3345918-reuters-google-will-resume-drug-treatment-ads-verification?source=tweet\" data-url=\"https://seekingalpha.com/news/3345918-reuters-google-will-resume-drug-treatment-ads-verification\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345915\" data-ts=\"1523906437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345915-russia-sanctions-halted-president-wapo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More Russia sanctions halted by president - WaPo</a></h4><ul><li>Short of any triggering event, the president<a href=\"https://www.washingtonpost.com/politics/trump-puts-the-brake-on-new-russian-sanctions-reversing-haleys-announcement/2018/04/16/ac3ad4f8-417f-11e8-8569-26fda6b404c7_story.html?noredirect=on&amp;utm_term=.2593d84ac5f4\" target=\"_blank\"> is unlikely to approve</a> of any more sanctions against Russia, reports the <em>Washington Post</em>.</li><li>That would seemingly contradict U.N. Ambassador Nikki Haley's Sunday comments that a new round of sanctions were imminent.</li><li>The VanEck Vectors Russia ETF (<a href='https://seekingalpha.com/symbol/RSX' title='VanEck Vectors Russia ETF'>RSX</a> <font color='green'>+2.1%</font>) has added to session gains.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/RSX' title='VanEck Vectors Russia ETF'>RSX</a>, <a href='https://seekingalpha.com/symbol/RUSL' title='Direxion Daily Russia Bull 3x Shares ETF'>RUSL</a>, <a href='https://seekingalpha.com/symbol/RUSS' title='Direxion Daily Russia Bear 3x Shares ETF'>RUSS</a>, <a href='https://seekingalpha.com/symbol/ERUS' title='iShares MSCI Russia Capped ETF'>ERUS</a>, <a href='https://seekingalpha.com/symbol/RSXJ' title='VanEck Vectors Russia Small-Cap ETF'>RSXJ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3345915\" data-linked=\"More Russia sanctions halted by president - WaPo\" data-tweet=\"$RSX $RUSL $RUSS - More Russia sanctions halted by president - WaPo https://seekingalpha.com/news/3345915-russia-sanctions-halted-president-wapo?source=tweet\" data-url=\"https://seekingalpha.com/news/3345915-russia-sanctions-halted-president-wapo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345914\" data-ts=\"1523906337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345914-fda-oks-bristol-myers-opdivo-yervoy-for-first-line-kidney-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Bristol-Myers&#39; Opdivo + Yervoy for first-line kidney cancer</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17130563-u-s-food-drug-administration-approves-opdivo-nivolumab-yervoy-ipilimumab-combination-first\" target=\"_blank\">approves </a>Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-8.4%</font>) combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma &#40;RCC&#41;.</li><li>The data supporting the indication was generated in the Phase 3 CheckMate-214 study that showed treatment with the combination significantly increased survival compared to Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+0.6%</font>) Sutent (sunitinib malate).</li></ul><div class=\"tiny-share-widget\" data-id=\"3345914\" data-linked=\"FDA OKs Bristol-Myers&#39; Opdivo + Yervoy for first-line kidney cancer\" data-tweet=\"$BMY $BMY $PFE - FDA OKs Bristol-Myers&#39; Opdivo + Yervoy for first-line kidney cancer https://seekingalpha.com/news/3345914-fda-oks-bristol-myers-opdivo-yervoy-for-first-line-kidney-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3345914-fda-oks-bristol-myers-opdivo-yervoy-for-first-line-kidney-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345913\" data-ts=\"1523905808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AWK\" target=\"_blank\">AWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345913-american-water-worksplus-2-janney-follows-pivotal-deal-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Water Works +2% as Janney follows Pivotal deal with upgrade</a></h4><ul>     <li>American Water Works (<a href='https://seekingalpha.com/symbol/AWK' title='American Water Works Company, Inc.'>AWK</a> <font color='green'>+2%</font>) is higher after Janney <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11521647/janney-upgrades-american-water-works-after-pivotal-acqu\" target=\"_blank\">upgrades shares to Buy</a> from Neutral woth a $92 price target, raised from $87, following <a href=\"https://seekingalpha.com/news/3345095-american-water-works-buy-pivotal-home-solutions-365m\" target=\"_blank\">last week's $365M purchase</a> of Pivotal Home Solutions.</li>     <li>The acquisition is timed to perfection, Janney says, as Pivotal can provide additional cash flow at a moment when utility dividends likely will turn unattractive vs. Treasury yields amid a rising rate environment.</li>     <li>The firm also notes that AWK now expects its EPS in the top half of its 7%-10% percent guidance range through 2022, and likes a purchase agreement the company recently signed for wastewater operations for the city of Alton, Ill., as offering a significant head start toward acquisition goals for 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345913\" data-linked=\"American Water Works +2% as Janney follows Pivotal deal with upgrade\" data-tweet=\"$AWK - American Water Works +2% as Janney follows Pivotal deal with upgrade https://seekingalpha.com/news/3345913-american-water-worksplus-2-janney-follows-pivotal-deal-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3345913-american-water-worksplus-2-janney-follows-pivotal-deal-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345912\" data-ts=\"1523905312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345912-technology-top-5-gainers-losers-of-3-00-pm-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 PM (04/16/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RUBI' title='The Rubicon Project, Inc.'>RUBI</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BDR' title='Blonder Tongue Laboratories, Inc'>BDR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/UAVS' title='AgEagle'>UAVS</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345912\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 PM (04/16/2018)\" data-tweet=\"$HMNY $HMNY $I - Technology - Top 5 Gainers / Losers as of 3:00 PM (04/16/2018) https://seekingalpha.com/news/3345912-technology-top-5-gainers-losers-of-3-00-pm-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345912-technology-top-5-gainers-losers-of-3-00-pm-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345910\" data-ts=\"1523904928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXY\" target=\"_blank\">OXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345910-occidental-petro-upped-piper-competitive-advantage-underappreciated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Occidental Petro upped at Piper as competitive advantage underappreciated</a></h4><ul>     <li>Occidental Petroleum (<a href='https://seekingalpha.com/symbol/OXY' title='Occidental Petroleum Corporation'>OXY</a> <font color='green'>+1.6%</font>) is higher after Piper Jaffray <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11522202/investors-underappreciate-occidental-petroleums-competi\" target=\"_blank\">upgrades</a> shares to Overweight from Neutral with an $86 price target, raised from $77, saying the stock has hit an inflection point with little downside ahead.</li>     <li>OXY's cash flow profile is rapidly improving, says Piper analyst Guy Baber, forecasting the company will revert to an organic free cash flow surplus during Q1 2018 for the first time since 2013.</li>     <li>Although investors understand OXY's strong Permian foothold, Baber says they have less appreciation for the degree to which OXY's size, scale, thoughtful approach to development and midstream integration have left it competitively advantaged relative to peers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345910\" data-linked=\"Occidental Petro upped at Piper as competitive advantage underappreciated\" data-tweet=\"$OXY - Occidental Petro upped at Piper as competitive advantage underappreciated https://seekingalpha.com/news/3345910-occidental-petro-upped-piper-competitive-advantage-underappreciated?source=tweet\" data-url=\"https://seekingalpha.com/news/3345910-occidental-petro-upped-piper-competitive-advantage-underappreciated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345908\" data-ts=\"1523904725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345908-alibabas-self-driving-tech-ready-for-open-road-testing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alibaba&#39;s self-driving tech ready for open road testing</a></h4><ul><li>        Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) is hiring 50 self-driving vehicle experts as it ramps up its testing program, according to the company-owned South China Morning Post (via <a href=\"https://www.engadget.com/2018/04/16/alibaba-china-testing-self-driving-vehicles/\" target=\"_blank\">Engadget</a>).</li><li>               Alibaba is working on Level 4 tech, which means the self-driving car can fully drive itself without human intervention in certain circumstances. The Morning Post says Alibaba&rsquo;s tech is ready for open road testing.&nbsp;</li><li>               Competitor Baidu last month received permission from the Chinese government to test its autonomous vehicle tech on roads in Beijing. Tencent also has that testing approval.&nbsp;</li><li>               Alibaba shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $173.79.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345908\" data-linked=\"Alibaba&#39;s self-driving tech ready for open road testing\" data-tweet=\"$BABA - Alibaba&#39;s self-driving tech ready for open road testing https://seekingalpha.com/news/3345908-alibabas-self-driving-tech-ready-for-open-road-testing?source=tweet\" data-url=\"https://seekingalpha.com/news/3345908-alibabas-self-driving-tech-ready-for-open-road-testing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345906\" data-ts=\"1523904252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBB\" target=\"_blank\">CBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345906-cincinnati-bell-claims-board-backing-from-iss-glass-lewis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cincinnati Bell claims board backing from ISS, Glass Lewis</a></h4><ul>   <li>Against a <a href=\"https://seekingalpha.com/news/3344059-gamco-seeks-election-three-cincinnati-bell-board\" target=\"_blank\">contesting board slate from Gamco</a>, Cincinnati Bell (<a href=\"http://seekingalpha.com/symbol/CBB\" target=\"_blank\">CBB</a> <font color='green'>+5.3%</font>) says it's gotten <a href=\"https://seekingalpha.com/pr/17130662-leading-proxy-advisory-firms-iss-glass-lewis-recommend-cincinnati-bell-shareholders-vote\" target=\"_blank\">backing from proxy advisers</a> ISS and Glass Lewis for all of its nominees.</li>    <li>The two firms noted that Gamco hasn't made a compelling case for change at the board level, the company says.</li>    <li>According to the company, as far as Gamco's opposition to the Hawaiian Telecom transaction, ISS says &ldquo;Gamco's limited disclosure makes it difficult for other shareholders to properly assess its case, given that its public critique is limited to a sole paragraph, which includes one sentence on the acquisition itself, with no analysis to support the dissident's underlying opposition to the transaction.&rdquo;</li>    <li>Cincinnati Bell has a slate of nine directors, while Gamco has offered up three of its own in place of the company's Craig Maier, Russel Mayer and Theodore Torbeck.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345906\" data-linked=\"Cincinnati Bell claims board backing from ISS, Glass Lewis\" data-tweet=\"$CBB - Cincinnati Bell claims board backing from ISS, Glass Lewis https://seekingalpha.com/news/3345906-cincinnati-bell-claims-board-backing-from-iss-glass-lewis?source=tweet\" data-url=\"https://seekingalpha.com/news/3345906-cincinnati-bell-claims-board-backing-from-iss-glass-lewis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345902\" data-ts=\"1523903712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345902-ubs-apple-wont-return-to-peak-sales-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS: Apple won&#39;t return to peak sales in China</a></h4><ul><li>        UBS <a href=\"https://www.cnbc.com/2018/04/16/no-turnaround-for-apple-in-china-due-to-smartphone-saturation-ubs.html\" target=\"_blank\">expects</a> Apple&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) sales growth in China this year to be roughly flat Y/Y.</li><li>               The firm cites a lengthening upgrade wait time and increasing local competition and doesn&rsquo;t expect Apple to return to its 2015 peak performance in the region. Apple&rsquo;s market share was 25% in 2015 and now stands at 19%.&nbsp;</li><li>               Firm maintains its Buy rating and $190 price target. &nbsp;&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;to $175.88.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345902\" data-linked=\"UBS: Apple won&#39;t return to peak sales in China\" data-tweet=\"$AAPL - UBS: Apple won&#39;t return to peak sales in China https://seekingalpha.com/news/3345902-ubs-apple-wont-return-to-peak-sales-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3345902-ubs-apple-wont-return-to-peak-sales-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345901\" data-ts=\"1523903621\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345901-quiet-place-nearly-holds-box-office-lead-from-rampage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Quiet Place&#39; nearly holds box-office lead from &#39;Rampage&#39;</a></h4><ul>   <li>With final figures in, the Rock and his <i>Rampage</i> (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='green'>+0.7%</font>) topped weekend box office in their debut, but not by much over a surprising second weekend from horror thriller <i>A Quiet Place</i> (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+2.1%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+1.7%</font>).</li>    <li><i>Rampage</i> grossed $35.8M compared to $32.6M logged by <i>A Quiet Place.</i> Another newcomer, horror film <i>Truth or Dare</i> (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+1.8%</font>), settled into third with $19.2M.</li>    <li><i>A Quiet Place</i> lost just a third of its opening-weekend business and stopped just shy of the $100M mark in early figures for cumulative domestic grosses, a much-needed score for Paramount. It's added another $51.7M overseas.</li>    <li>Rounding out the top five were <i>Ready Player One</i> (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) at No. 4 with $11.5M and <i>Blockers</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) at No. 5 with $10.3M.</li>    <li>Among still-running hits, <i>Black Panther</i> (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-0.1%</font>) is still in more than 2,000 theaters and added another $5.3M to bring domestic grosses to $673.8M, and worldwide to $1.31B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345901\" data-linked=\"&#39;Quiet Place&#39; nearly holds box-office lead from &#39;Rampage&#39;\" data-tweet=\"$VIA $VIA $VIAB - &#39;Quiet Place&#39; nearly holds box-office lead from &#39;Rampage&#39; https://seekingalpha.com/news/3345901-quiet-place-nearly-holds-box-office-lead-from-rampage?source=tweet\" data-url=\"https://seekingalpha.com/news/3345901-quiet-place-nearly-holds-box-office-lead-from-rampage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345898\" data-ts=\"1523902639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345898-geminus-1_5-goldman-warns-of-reduced-2018-profit-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE -1.5% as Goldman warns of reduced 2018 profit outlook</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-1.5%</font>) falls the most among Dow stocks after Goldman Sachs says GE <a href=\"https://www.bloomberg.com/news/articles/2018-04-16/ge-falls-most-on-dow-as-goldman-warns-of-cut-to-profit-forecast\" target=\"_blank\">may need to cut its 2018 earnings forecast</a> after the company released its much-anticipated <a href=\"https://seekingalpha.com/news/3345655-ge-reports-expected-restated-2016minus-17-earnings-4_2b-q1-charge\" target=\"_blank\">restated financials</a>.</li>     <li>While GE had warned investors about the change and the actual figures were &ldquo;more benign than bear-case expectations,&rdquo; last year&rsquo;s revised profit still was worse than the company had suggested, making a cut to the 2018 outlook &ldquo;almost a certainty&rdquo; and perhaps coming as soon as GE's Q1 report later this week, says Goldman's Joe Ritchie.</li>     <li>GE expects \"no impact\" to its 2018 forecast from the restatement, and some analysts agree; Barclays believes the restatement might be a positive \"if we look at GE from the standpoint of &rsquo;one less shoe to drop,' as this is another hurdle that has now been cleared, but more significant events remain ahead.\"</li>     <li>Melius Research says GE could still reach $1/share in adjusted earnings through cost cuts, and the fact that GE didn&rsquo;t cut its forecast along with the restatements &ldquo;seems like a good sign.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345898\" data-linked=\"GE -1.5% as Goldman warns of reduced 2018 profit outlook\" data-tweet=\"$GE - GE -1.5% as Goldman warns of reduced 2018 profit outlook https://seekingalpha.com/news/3345898-geminus-1_5-goldman-warns-of-reduced-2018-profit-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3345898-geminus-1_5-goldman-warns-of-reduced-2018-profit-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345892\" data-ts=\"1523901616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSN\" target=\"_blank\">OSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345892-energy-materials-top-5-gainers-losers-of-2-00-pm-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm (04/16/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/UUUU' title='Energy Fuels Inc'>UUUU</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ENLK' title='EnLink Midstream Partners, LP'>ENLK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CEIX' title='CONSOL Energy Inc.'>CEIX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NOV' title='National Oilwell Varco, Inc.'>NOV</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345892\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm (04/16/2018)\" data-tweet=\"$OSN $OSN $UEC - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm (04/16/2018) https://seekingalpha.com/news/3345892-energy-materials-top-5-gainers-losers-of-2-00-pm-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345892-energy-materials-top-5-gainers-losers-of-2-00-pm-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345886\" data-ts=\"1523898973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345886-health-insurers-managed-care-firms-up-ahead-of-unh-q1-earnings-tomorrow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health insurers/managed care firms up ahead of UNH Q1 earnings tomorrow</a></h4><ul><li>The market's up day notwithstanding, health insurance and managed care stocks are up as a group. UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+2.7%</font>) kicks off the healthcare earnings season tomorrow premarket. Consensus view is EPS of $2.91 (<font color='green'>+191%</font>) on revenues of $54.8B (<font color='green'>+13%</font>).</li><li>Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='green'>+1.2%</font>) is first up in the biopharma space, also due to report tomorrow premarket. Consensus view is EPS of $2.00 (<font color='green'>+9%</font>) on revenues of $19.4B (<font color='green'>+9%</font>).</li><li>Q1 is the first reporting period based on the lower corporate tax rate.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+2.1%</font>)(<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a> <font color='green'>+1.9%</font>)(<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+1.2%</font>)(<a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='green'>+1.7%</font>)(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345886\" data-linked=\"Health insurers/managed care firms up ahead of UNH Q1 earnings tomorrow\" data-tweet=\"$UNH $UNH $JNJ - Health insurers/managed care firms up ahead of UNH Q1 earnings tomorrow https://seekingalpha.com/news/3345886-health-insurers-managed-care-firms-up-ahead-of-unh-q1-earnings-tomorrow?source=tweet\" data-url=\"https://seekingalpha.com/news/3345886-health-insurers-managed-care-firms-up-ahead-of-unh-q1-earnings-tomorrow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345879\" data-ts=\"1523898059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMTS\" target=\"_blank\">PMTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345879-financials-top-gainers-losers-of-1-00-pm-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (04/16/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/RVEN' title='Reven Housing REIT, Inc.'>RVEN</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CART' title='Carolina Trust Bank'>CART</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345879\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (04/16/2018)\" data-tweet=\"$PMTS $PMTS $RVEN - Financials - Top Gainers / Losers as of 1:00 PM (04/16/2018) https://seekingalpha.com/news/3345879-financials-top-gainers-losers-of-1-00-pm-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345879-financials-top-gainers-losers-of-1-00-pm-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345880\" data-ts=\"1523898045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPHI\" target=\"_blank\">IPHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345880-jpmorgan-defends-inphi-on-zte-related-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan defends Inphi on ZTE-related weakness</a></h4><ul><li>           JPMorgan <a href=\"https://www.streetinsider.com/Analyst+Comments/Inphi+Corp.+%28IPHI%29+Defended+at+JPMorgan%2C+Says+Buy+On+Weakness/14058317.html\" target=\"_blank\">defends</a> Inphi (NYSE:<a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a>) on selloff after the U.S. Department of Commerce denied export privileges to ZTE, which accounts for a small amount of Inphi&rsquo;s revenue. </li><li> Firm maintains an Overweight rating on Inphi and recommends buying on weakness. </li><li> Inphi shares are&nbsp;<font color='red'>down 5%</font>&nbsp;to $31.10.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3345880\" data-linked=\"JPMorgan defends Inphi on ZTE-related weakness\" data-tweet=\"$IPHI - JPMorgan defends Inphi on ZTE-related weakness https://seekingalpha.com/news/3345880-jpmorgan-defends-inphi-on-zte-related-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3345880-jpmorgan-defends-inphi-on-zte-related-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345877\" data-ts=\"1523897848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345877-stocks-session-highs-in-afternoon-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks at session highs in afternoon action</a></h4><ul><li>A modest early gain has grown into a more sizable advance, with the S&amp;P 500&nbsp;<font color='green'>up 1%</font>&nbsp;and the Dow&nbsp;<font color='green'>ahead 1.2%</font>&nbsp;at around 1 ET. The Nasdaq is&nbsp;<font color='green'>higher by 0.85%</font>.</li><li>It's a broad move, led by the industrials (<a href='https://seekingalpha.com/symbol/XLI' title='Industrial Select Sector SPDR ETF'>XLI</a> <font color='green'>+1.2%</font>) and building materials (<a href='https://seekingalpha.com/symbol/XLB' title='Materials Select Sector SPDR ETF'>XLB</a> <font color='green'>+1.1%</font>), as trade war chatter has calmed a bit.</li><li>The 10-year Treasury yield is up 1.3 basis points to 2.84%. Gold is modestly in the green, and oil is<font color='red'> down 1.2%</font>&nbsp;to $66.56.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345877\" data-linked=\"Stocks at session highs in afternoon action\" data-tweet=\"$XLI $XLB - Stocks at session highs in afternoon action https://seekingalpha.com/news/3345877-stocks-session-highs-in-afternoon-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3345877-stocks-session-highs-in-afternoon-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345873\" data-ts=\"1523897230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345873-vmwareplus-6_8-dell-leans-against-reverse-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VMware +6.8% as Dell leans against reverse merger</a></h4><ul><li>        VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>) shares are<font color='green'>&nbsp;</font><font color='green'>up 6.8%</font>&nbsp;today after the weekend&rsquo;s <a href=\"https://www.barrons.com/articles/vmware-speculation-of-no-dell-deal-is-a-good-deal-for-the-stock-1523888145\" target=\"_blank\">Bloomberg report</a> that Dell (DVMT) is &ldquo;leaning against&rdquo; the reverse merger idea.</li><li>               Analyst action: Credit Suisse reiterates an Outperform rating on VMware, calling the report an &ldquo;incremental positive&rdquo; for VMware.&nbsp;</li><li>                  Dell&rsquo;s tracking stock is&nbsp;<font color='green'>up 2.7%</font>&nbsp;to $74.83.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3335805-cnbc-dell-vmware-reverse-merger-decision-come-soon\" target=\"_blank\">CNBC: Dell, VMware reverse merger decision could come soon</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345873\" data-linked=\"VMware +6.8% as Dell leans against reverse merger\" data-tweet=\"$VMW $VMW $DELL - VMware +6.8% as Dell leans against reverse merger https://seekingalpha.com/news/3345873-vmwareplus-6_8-dell-leans-against-reverse-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3345873-vmwareplus-6_8-dell-leans-against-reverse-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345872\" data-ts=\"1523897141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GKOS\" target=\"_blank\">GKOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345872-glaukos-istent-reduces-iop-in-cataract-surgery-patients-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaukos iStent reduces IOP in cataract surgery patients; shares up 3%</a></h4><ul><li>Glaukos (<a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+3.3%</font>) tries to claw back after its recent selloff. Shares are up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/17129515-ide-pivotal-trial-results-glaukos-istent-inject-show-significant-reductions-unmedicated-iop\" target=\"_blank\">announcement </a>of positive results from a 505-subject pivotal trial assessing the iStent Inject Trabecular Micro-Bypass System for lowering intraocular pressure &#40;IOP&#41; in patients undergoing cataract surgery. The data were presented at the American Society for Cataract and Refractive Surgery Annual Meeting in Washington, D.C.</li><li>At month 24, 75.3% (n=291/387) of patients receiving the iStent experienced at least a 20% drop in unmedicated IOP compared to 61.9% (n=73/118) of those undergoing cataract surgery only. The average drop in unmedicated IOP also favored the iStent cohort, 6.9 mmHg vs. 5.4 mmHg.</li><li>The company's U.S. marketing application for iStent Inject is currently under FDA review. The device is currently approved in the EU, Armenia, Australia, Brazil, Canada, Hong Kong, Singapore and South Africa.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345518-stifel-softens-view-glaukos-sees-competitive-inroads-ivantis-shares-slip-5-percent-premarket\" target=\"_blank\">Stifel softens view on Glaukos, sees competitive inroads from Ivantis; shares slip 5% premarket</a> (April 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345872\" data-linked=\"Glaukos iStent reduces IOP in cataract surgery patients; shares up 3%\" data-tweet=\"$GKOS - Glaukos iStent reduces IOP in cataract surgery patients; shares up 3% https://seekingalpha.com/news/3345872-glaukos-istent-reduces-iop-in-cataract-surgery-patients-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3345872-glaukos-istent-reduces-iop-in-cataract-surgery-patients-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345870\" data-ts=\"1523896856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSN\" target=\"_blank\">OSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345870-midday-gainers-losers-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (04/16/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SHOS' title='Sears Hometown and Outlet Stores, Inc.'>SHOS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/FTD' title='FTD Companies, Inc.'>FTD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/FSCT' title='ForeScout Technologies, Inc.'>FSCT</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/BXC' title='BlueLinx Holdings, Inc.'>BXC</a> <font color='green'>+11%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='red'>-64%</font>. <a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/NVMM' title='NOVUME SOLUTIONS INC'>NVMM</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics'>LPTX</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/CYAN' title='Cyanotech Corporation'>CYAN</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a> <font color='red'>-11%</font>.</li> &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3345870\" data-linked=\"Midday Gainers / Losers (04/16/2018)\" data-tweet=\"$OSN $OSN $ERI - Midday Gainers / Losers (04/16/2018) https://seekingalpha.com/news/3345870-midday-gainers-losers-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345870-midday-gainers-losers-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345867\" data-ts=\"1523896096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNPS\" target=\"_blank\">SNPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345867-synopsys-and-arm-extend-subscription-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synopsys and Arm extend subscription agreement</a></h4><ul><li>           Synopsys (NASDAQ:<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a>) and Arm <a href=\"https://seekingalpha.com/pr/17130220-synopsys-arm-extend-collaboration-improve-power-performance-time-results-arms-latest-ip\" target=\"_blank\">extend</a> an existing collaboration and sign a multiyear subscription agreement allowing Synopsys to access Arm IP. </li><li> Synopsys will get early access to Arm Cortex CPUs, Mali GPUs, CoreLink system IP, Artisan physical IP, and POP IP to optimize Synopsys&rsquo; tools and methodologies for Arm-based SoCs. </li><li> The duo will share the results of the collaboration at worldwide workshops staring on April 25 in Tokyo. </li><li> Synopsys shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;to $84.37.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3345867\" data-linked=\"Synopsys and Arm extend subscription agreement\" data-tweet=\"$SNPS - Synopsys and Arm extend subscription agreement https://seekingalpha.com/news/3345867-synopsys-and-arm-extend-subscription-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3345867-synopsys-and-arm-extend-subscription-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345865\" data-ts=\"1523895711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCJ\" target=\"_blank\">CCJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345865-camecoplus-6-on-report-russia-considers-banning-uranium-exports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cameco +6% on report that Russia considers banning uranium exports</a></h4><ul>     <li>Cameco (<a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+5.9%</font>) spikes higher after Russia is said to be <a href=\"https://twitter.com/thenotablecalls/status/985909082589749248\" target=\"_blank\">preparing a ban of uranium exports</a>, a move that would help the company as Russia represents 40% of U.S. imports.</li><li>A draft bill was submitted to Russia's Duma, the lower house of the country's parliament, that would <a href=\"https://twitter.com/thenotablecalls/status/985909541236805632\" target=\"_blank\">ban all trade</a> between state-owned nuclear power company Rosatom and U.S. nuclear power companies, according to TD&nbsp;Securities.</li><li>The bill could be considered and possibly adopted during the next Duma session next week, TD says.</li><li>Denison Mines (<a href='https://seekingalpha.com/symbol/DNN' title='Denison Mines Corp'>DNN</a> <font color='green'>+6.1%</font>) also powers higher following the report.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/NLR' title='VanEck Vectors Uranium+Nuclear Energy ETF'>NLR</a>, <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3345865\" data-linked=\"Cameco +6% on report that Russia considers banning uranium exports\" data-tweet=\"$CCJ $CCJ $DNN - Cameco +6% on report that Russia considers banning uranium exports https://seekingalpha.com/news/3345865-camecoplus-6-on-report-russia-considers-banning-uranium-exports?source=tweet\" data-url=\"https://seekingalpha.com/news/3345865-camecoplus-6-on-report-russia-considers-banning-uranium-exports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345857\" data-ts=\"1523894907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMC\" target=\"_blank\">MMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345857-marsh-ibm-collaborate-on-blockchain-proof-of-insurance-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marsh, IBM collaborate on blockchain proof of insurance product</a></h4><ul><li>        Marsh (NYSE:<a href='https://seekingalpha.com/symbol/MMC' title='Marsh & McLennan Companies, Inc.'>MMC</a>) is <a href=\"https://seekingalpha.com/pr/17130443-marsh-collaborates-ibm-acord-isn-apply-blockchain-technology-first-commercial-proof-insurance\" target=\"_blank\">collaborating</a> with IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>), ACORD, and ISN to create the first commercial blockchain solution for proof of insurance.</li><li>               The project hopes to offer proof of insurance in a way that maximizes efficiency while maintaining accuracy due to blockchain&rsquo;s distributed ledger technology.&nbsp;</li><li>               The project uses the open source Hyperledger Fabric tech and IBM&rsquo;s Blockchain Platform. Marsh and IBM will develop the insurance solution with input from ACORD and customer feedback from ISN.&nbsp;</li><li>               The network will go into production later this year and Marsh client ISN will be the first to pilot the project.&nbsp;</li><li>                  Marsh &amp; McLennan shares are&nbsp;<font color='green'>up 2.3%</font>&nbsp;to $83.91.    </li><li>               IBM shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;to $158.68.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345857\" data-linked=\"Marsh, IBM collaborate on blockchain proof of insurance product\" data-tweet=\"$MMC $MMC $IBM - Marsh, IBM collaborate on blockchain proof of insurance product https://seekingalpha.com/news/3345857-marsh-ibm-collaborate-on-blockchain-proof-of-insurance-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3345857-marsh-ibm-collaborate-on-blockchain-proof-of-insurance-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345854\" data-ts=\"1523894438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345854-consumer-top-gainers-losers-of-12-00-pm-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (04/16/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345854\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (04/16/2018)\" data-tweet=\"$NAV $NAV $CAAS - Consumer - Top Gainers / Losers as of 12:00 PM (04/16/2018) https://seekingalpha.com/news/3345854-consumer-top-gainers-losers-of-12-00-pm-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345854-consumer-top-gainers-losers-of-12-00-pm-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345849\" data-ts=\"1523893602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPE\" target=\"_blank\">HPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345849-hewlett-packard-enterprise-teams-up-for-uk-supercomputer-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hewlett Packard Enterprise teams up for UK supercomputer project</a></h4><ul><li>           Hewlett Packard Enterprise (NYSE:<a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a>) <a href=\"https://seekingalpha.com/pr/17129842-academia-industry-collaborate-drive-uk-supercomputer-adoption\" target=\"_blank\">announces collaborating</a> with Arm, SUSE, and three UK universities to accelerate supercomputer application adoption in the region. </li><li> The partners will develop and deploy &ldquo;one of the largest Arm-based high-performance computing installations in the world,&rdquo; which will be available for both enterprise and academic purposes. </li><li> HPE designed and built the deployment that will spread across sites at the University of Edinburgh, the University of Bristol, and the University of Leicester. </li><li> The installation should complete this summer and will run for three years as part of the Catalyst UK project. </li><li> HPE shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;to $17.51.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3345849\" data-linked=\"Hewlett Packard Enterprise teams up for UK supercomputer project\" data-tweet=\"$HPE - Hewlett Packard Enterprise teams up for UK supercomputer project https://seekingalpha.com/news/3345849-hewlett-packard-enterprise-teams-up-for-uk-supercomputer-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3345849-hewlett-packard-enterprise-teams-up-for-uk-supercomputer-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345846\" data-ts=\"1523893002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPTX\" target=\"_blank\">LPTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345846-investors-underwhelmed-leaps-early-stage-dknminus-01-data-shares-down-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors underwhelmed with Leap&#39;s early-stage DKN-01 data; shares down 23%</a></h4><ul><li>Thinly traded micro cap Leap Therapeutics (<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics'>LPTX</a> <font color='red'>-23.1%</font>) slumps on almost triple normal volume, albeit on turnover of only 321K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/17130117-leap-therapeutics-presents-nonclinical-clinical-data-dknminus-01-aacr-2018-annual-meeting\" target=\"_blank\">announcement </a>of preliminary results from the dose-escalation phase of its study assessing DKN-01 with Merck's KEYTRUDA (pembrolizumab) in patients with advanced esophagogastric cancer.</li><li>In four evaluable patients naive to PD-inhibitor treatment, one experienced a partial response with a 66% reduction in target tumor volume while two had stable disease.</li><li>Enrollment is ongoing.</li><li><a href=\"http://www.leaptx.com/science/#modulate-wnt-signaling\" target=\"_blank\">DKN-01</a>&nbsp;is a humanized IgG4 monoclonal antibody that binds to&nbsp;<a href=\"https://en.wikipedia.org/wiki/DKK1\" target=\"_blank\">Dickkopf-1</a>&nbsp;(DKK1), a protein associated with a poor prognosis in a range of cancers. Specifically, it inhibits a pathway called canonical Wnt/Beta-catenin which plays a key role in embryonic development, cell proliferation and differentiation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345846\" data-linked=\"Investors underwhelmed with Leap&#39;s early-stage DKN-01 data; shares down 23%\" data-tweet=\"$LPTX - Investors underwhelmed with Leap&#39;s early-stage DKN-01 data; shares down 23% https://seekingalpha.com/news/3345846-investors-underwhelmed-leaps-early-stage-dknminus-01-data-shares-down-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3345846-investors-underwhelmed-leaps-early-stage-dknminus-01-data-shares-down-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345843\" data-ts=\"1523892353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RUALF\" target=\"_blank\">RUALF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345843-aluminum-hits-highest-in-six-plus-years-rusal-supply-seen-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aluminum hits highest in six-plus years as Rusal supply seen at risk</a></h4><ul>     <li><a href=\"https://www.bloomberg.com/news/articles/2018-04-16/aluminum-hits-new-six-year-high-with-rusal-supply-seen-at-risk\" target=\"_blank\">Aluminum prices extend last week&rsquo;s big gain</a> following U.S. sanctions on major Russian producer Rusal, <a href=\"https://www.wsj.com/articles/aluminum-extends-sanction-driven-gains-1523889189\" target=\"_blank\">jumping another 3.7%</a> on the LME to $2,371/metric ton and touching the highest level since late 2011.</li>     <li>&ldquo;We have a potential scenario where U.S. and European markets will be shut off to Rusal, and they&rsquo;ll be forced to redirect units to clients in other markets,&rdquo; Deutsche Bank metals analyst Nicholas Snowdon tells Bloomberg. &ldquo;There&rsquo;s clear potential that [Rusal] will have to cut production.&rdquo;</li>     <li>Aluminum stockpiles in LME warehouses add another 1.1% following last week&rsquo;s 6.7% surge, as traders sought to deposit Rusal (<a href='https://seekingalpha.com/symbol/RUALF' title='United Company Rusal PLC'>OTC:RUALF</a>) metal before tomorrow's deadline after the LME said it would stop accepting the sanctioned firm&rsquo;s supplies.</li><li>Alcoa (<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='green'>+1.4%</font>), <a href=\"https://seekingalpha.com/news/3345654-alcoa-keep-benefiting-higher-prices-cowen-analyst-says\" target=\"_blank\">seen as a beneficiary</a> from the price gains, is higher; also, <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/KALU' title='Kaiser Aluminum Corporation'>KALU</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a> <font color='green'>+0.4%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJU-OLD' title='iPath Dow Jones-UBS Aluminum Total Return Sub-IndexS ETN'>JJU-OLD</a>, <a href='https://seekingalpha.com/symbol/FOIL' title='iPath Pure Beta Aluminum ETN'>FOIL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3345843\" data-linked=\"Aluminum hits highest in six-plus years as Rusal supply seen at risk\" data-tweet=\"$RUALF $RUALF $AA - Aluminum hits highest in six-plus years as Rusal supply seen at risk https://seekingalpha.com/news/3345843-aluminum-hits-highest-in-six-plus-years-rusal-supply-seen-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3345843-aluminum-hits-highest-in-six-plus-years-rusal-supply-seen-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345841\" data-ts=\"1523892149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLVF\" target=\"_blank\">ALLVF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345841-altice-issues-jump-amid-bouygues-interest-in-french-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altice issues jump amid Bouygues interest in French unit</a></h4><ul>     <li>Shares in Altice <font color='green'>jumped 5%</font> in Amsterdam, and <a href='https://seekingalpha.com/symbol/ALLVF' title='Altice Europe N V'>OTCPK:ALLVF</a> is <font color='green'>up 3.7%</font>, on Bloomberg's report that Bouygues (<a href='https://seekingalpha.com/symbol/BOUYF' title='Bouygues SA'>OTCPK:BOUYF</a> <font color='red'>-0.7%</font>) is considering leading a bid for Altice's struggling French unit.</li>     <li>Bouygues has held early talks with investment firms like CVC about the prospect of taking over Altice France and its SFR Group, according to the report.</li>     <li>Shares in Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) are <font color='green'>up 3.2%</font> as well, moving on a trajectory like that of its parent company.</li>   <li>Other French telecoms are moving in sympathy: Orange (NYSE:<a href='https://seekingalpha.com/symbol/ORAN' title='Orange'>ORAN</a>) is <font color='green'>up 1.6%</font>; Iliad (<a href='https://seekingalpha.com/symbol/ILIAY' title='Iliad Akt ADR'>OTCPK:ILIAY</a>) <font color='green'>up 5.7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3345841\" data-linked=\"Altice issues jump amid Bouygues interest in French unit\" data-tweet=\"$ALLVF $ALLVF $BOUYF - Altice issues jump amid Bouygues interest in French unit https://seekingalpha.com/news/3345841-altice-issues-jump-amid-bouygues-interest-in-french-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3345841-altice-issues-jump-amid-bouygues-interest-in-french-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345838\" data-ts=\"1523892085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAAP\" target=\"_blank\">CAAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345838-corporacion-america-up-4-after-seeking-alpha-mention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corporacion America up more than 4% after Seeking Alpha mention</a></h4><ul><li><a href=\"https://seekingalpha.com/article/4163083-corporacion-america-capitalizing-argentinas-aviation-sector-renaissance\" target=\"_blank\">A bullish item on</a>&nbsp;Corporacion America (<a href='https://seekingalpha.com/symbol/CAAP' title='Corporacion America Airports SA'>CAAP</a> <font color='green'>+4.4%</font>) by Free Cash Flow 50 is Seeking Alpha's Top Idea of the Day.</li><li>Argentina is one of the few untapped nations left for low-cost carriers to enter, says the author, but the government is set on reforming archaic airline policies, with the goal of doubling air traffic over the next four years. Corporacion America is perfectly positioned to benefit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345838\" data-linked=\"Corporacion America up more than 4% after Seeking Alpha mention\" data-tweet=\"$CAAP - Corporacion America up more than 4% after Seeking Alpha mention https://seekingalpha.com/news/3345838-corporacion-america-up-4-after-seeking-alpha-mention?source=tweet\" data-url=\"https://seekingalpha.com/news/3345838-corporacion-america-up-4-after-seeking-alpha-mention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345832\" data-ts=\"1523890843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OASM\" target=\"_blank\">OASM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345832-healthcare-top-5-gainers-losers-of-11-00-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (04/16/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MYND' title='MYnd Analytics, Inc.'>MYND</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/BVX' title='Bovie Medical Corporation'>BVX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='red'>-60%</font>. <a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics'>LPTX</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CYAN' title='Cyanotech Corporation'>CYAN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CERC' title='Cerecor'>CERC</a> <font color='red'>-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345832\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (04/16/2018)\" data-tweet=\"$OASM $OASM $EMMA - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (04/16/2018) https://seekingalpha.com/news/3345832-healthcare-top-5-gainers-losers-of-11-00-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345832-healthcare-top-5-gainers-losers-of-11-00-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345831\" data-ts=\"1523890802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPCO\" target=\"_blank\">TPCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345831-tronc-halted-on-9_2-spike-softbank-linked-to-bidding-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tronc halted on 9.2% spike; SoftBank linked to bidding (updated)</a></h4><ul>     <li>Tronc (TRNC) has been halted on a circuit breaker, <font color='green'>up 9.2%</font>.</li>     <li>Fellow publisher Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>) is also suddenly <font color='green'>up 2.2%</font>.</li>   <li>SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) is among the <a href=\"https://www.axios.com/tronc-gannett-apollo-softbank-investors-b54fa97d-2365-4575-a37e-f7ec4f088d2d.html?utm_source=sidebar\" target=\"_blank\">potential buyers for Tronc</a>, Axios reports, joining firms like Apollo (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>). Gannett's still in the mix as well, Axios says.</li><li><strong>Updated 11:05 a.m.:</strong>&nbsp;Tronc resumed trading after a short halt, now <font color='green'>up 6.8%</font>; <a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a> <font color='green'>up 1.7%</font>; <a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a> <font color='green'>up 0.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345831\" data-linked=\"Tronc halted on 9.2% spike; SoftBank linked to bidding (updated)\" data-tweet=\"$TPCO $TPCO $GCI - Tronc halted on 9.2% spike; SoftBank linked to bidding (updated) https://seekingalpha.com/news/3345831-tronc-halted-on-9_2-spike-softbank-linked-to-bidding-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3345831-tronc-halted-on-9_2-spike-softbank-linked-to-bidding-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345828\" data-ts=\"1523890610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSM\" target=\"_blank\">TSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345828-tsmc-will-report-slight-revenue-increase-in-q2-say-market-watchers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TSMC will report slight revenue increase in Q2, say market watchers</a></h4><ul><li>        Taiwan Semiconductor Manufacturing Co. (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) will report low sequential revenue growth in Q2, <a href=\"https://www.digitimes.com/news/a20180416VL201.html\" target=\"_blank\">according to estimates</a> from local market watchers via Economic Daily News and Commercial Times.</li><li>               The market watchers estimate a 3% sequential increase in Q2 revenues offset by a 1% to 2% drop in demand for ASICs and handset chips.&nbsp;</li><li>               The performance estimate is blamed on ASIC demand slowdown for cryptocurrency mining.&nbsp;</li><li>               TSMC will report Q2 earnings on April 19.&nbsp;</li><li>               TSMC shares are&nbsp;<font color='green'>up 0.5%</font>&nbsp;to $42.86.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345828\" data-linked=\"TSMC will report slight revenue increase in Q2, say market watchers\" data-tweet=\"$TSM - TSMC will report slight revenue increase in Q2, say market watchers https://seekingalpha.com/news/3345828-tsmc-will-report-slight-revenue-increase-in-q2-say-market-watchers?source=tweet\" data-url=\"https://seekingalpha.com/news/3345828-tsmc-will-report-slight-revenue-increase-in-q2-say-market-watchers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345827\" data-ts=\"1523890549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORIG\" target=\"_blank\">ORIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345827-ocean-rig-announces-150m-stock-buyback-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocean Rig announces $150M stock buyback plan</a></h4><ul>     <li>Ocean Rig UDW&nbsp;(<a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='green'>+4.3%</font>) jumps after its board authorizes a <a href=\"https://seekingalpha.com/pr/17130078-ocean-rig-udw-inc-announces-authorization-150-million-stock-repurchase-plan\" target=\"_blank\">$150M stock repurchase plan</a> over the next 12 months.</li>     <li>The company expects to finance the stock purchases with existing cash balances.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345827\" data-linked=\"Ocean Rig announces $150M stock buyback plan\" data-tweet=\"$ORIG - Ocean Rig announces $150M stock buyback plan https://seekingalpha.com/news/3345827-ocean-rig-announces-150m-stock-buyback-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3345827-ocean-rig-announces-150m-stock-buyback-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345824\" data-ts=\"1523890168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345824-alnylam-down-3-on-early-stage-givosiran-data-in-ahp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam down 3% on early-stage givosiran data in AHP</a></h4><ul><li>Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='red'>-2.9%</font>) is down, albeit on light volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17129493-alnylam-presents-new-positive-clinical-results-givosiran-investigational-rnai-therapeutic\" target=\"_blank\">announcement </a>of new data from its open-label extension studies of RNAi therapeutic givosiran in patients with acute hepatic porphyrias (AHPs). The results were presented at the International LIver Congress in Paris.</li><li>Treatment with givosiran lowered aminolevulinic acid &#40;ALA&#41;, the primary toxin in AFPs, and a compound called porphobilinogen &#40;PBG&#41; which led to an 83% decrease in annualized attack rate &#40;AAR&#41;&nbsp;compared to placebo. The average reduction in AAR was 93% in patients treated in the Phase 1 study who continued treatment in the extension portion (n=11/12).</li><li>Investors appear disappointed that the higher monthly dose of givosran (5.0 mg/kg) did not lower ALA and PBG levels further compared to the lower dose (2.5 mg/kg). Also, the monthly regimen was more effective than the quarterly regimen dashing hopes for less-frequent administration.</li><li>The other bit of bad news was one case of a serious allergic reaction to givosiran after the third dose. The situation was resolved but the patient withdrew from the study.</li><li>Enrollment in the Phase 3 ENVISION trial is proceeding with interim data expected mid-year. If positive, the company intends to file a U.S. marketing application.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3309063-alnylam-launches-late-stage-study-assessing-givosiran-ahps\" target=\"_blank\">Alnylam launches late-stage study assessing givosiran in AHPs</a> (Nov. 7, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345824\" data-linked=\"Alnylam down 3% on early-stage givosiran data in AHP\" data-tweet=\"$ALNY - Alnylam down 3% on early-stage givosiran data in AHP https://seekingalpha.com/news/3345824-alnylam-down-3-on-early-stage-givosiran-data-in-ahp?source=tweet\" data-url=\"https://seekingalpha.com/news/3345824-alnylam-down-3-on-early-stage-givosiran-data-in-ahp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345825\" data-ts=\"1523890123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLSN\" target=\"_blank\">NLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345825-nielsenplus-1_9-bmo-upgrades-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nielsen +1.9% as BMO upgrades to Outperform</a></h4><ul>   <li>Nielsen Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings N.V.'>NLSN</a>) is <font color='green'>up 1.9%</font> after an upgrade to Outperform at BMO Capital Markets.</li>    <li>The firm boosted its stance from Market Perform, and gave Nielsen a $38 price target, implying 15% upside from the current price.</li>    <li>Nielsen shares are <font color='red'>down 21%</font> over the past year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345825\" data-linked=\"Nielsen +1.9% as BMO upgrades to Outperform\" data-tweet=\"$NLSN - Nielsen +1.9% as BMO upgrades to Outperform https://seekingalpha.com/news/3345825-nielsenplus-1_9-bmo-upgrades-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3345825-nielsenplus-1_9-bmo-upgrades-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345823\" data-ts=\"1523889941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOHU\" target=\"_blank\">SOHU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345823-sohu-com-enters-credit-facility-agreement-makes-initial-drawdown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sohu.com enters credit facility agreement, makes initial drawdown</a></h4><ul><li>        Sohu.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Limited'>SOHU</a>) <a href=\"https://seekingalpha.com/filing/3976866\" target=\"_blank\">enters</a> into a credit facility agreement with China Merchants Bank that allows the company to borrow up to about $111.27M.</li><li>                  The company has made an initial drawdown of about $63.58M under the loan.    </li><li>               Sohu shares are&nbsp;<font color='red'>down 2.5%</font>&nbsp;to $32.94.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345823\" data-linked=\"Sohu.com enters credit facility agreement, makes initial drawdown\" data-tweet=\"$SOHU - Sohu.com enters credit facility agreement, makes initial drawdown https://seekingalpha.com/news/3345823-sohu-com-enters-credit-facility-agreement-makes-initial-drawdown?source=tweet\" data-url=\"https://seekingalpha.com/news/3345823-sohu-com-enters-credit-facility-agreement-makes-initial-drawdown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345820\" data-ts=\"1523889310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSM\" target=\"_blank\">FSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345820-fortuna-silver-mines-reports-gains-in-q1-gold-silver-production\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortuna Silver Mines reports gains in Q1 gold, silver production</a></h4><ul>     <li>Fortuna SIlver Mines (<a href='https://seekingalpha.com/symbol/FSM' title='Fortuna Silver Mines'>FSM</a> <font color='green'>+1.4%</font>) is higher after reporting <a href=\"https://seekingalpha.com/pr/17129651-fortuna-reports-production-2_4-million-ounces-silver-15041-ounces-gold-first-quarter-2018\" target=\"_blank\">Q1 silver production rose 18% Y/Y</a> to more than 2.4M oz. and gold production climbed 14% Y/Y to 15K oz.</li>     <li>FSM says the San Jose mine in Mexico produced 2.18M silver oz. and nearly 14.9K gold oz. in the quarter, a respective 19% and 22% above budget, citing a change in the planned mining sequence for the quarter and higher than expected grades at level 1000.</li>     <li>FSM says it is on schedule to meet annual production guidance of 8.3M&nbsp;oz. of silver and 48.3K oz. of gold, or 11.4M gold equiv. oz., in 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345820\" data-linked=\"Fortuna Silver Mines reports gains in Q1 gold, silver production\" data-tweet=\"$FSM - Fortuna Silver Mines reports gains in Q1 gold, silver production https://seekingalpha.com/news/3345820-fortuna-silver-mines-reports-gains-in-q1-gold-silver-production?source=tweet\" data-url=\"https://seekingalpha.com/news/3345820-fortuna-silver-mines-reports-gains-in-q1-gold-silver-production\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345817\" data-ts=\"1523888788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNRO\" target=\"_blank\">MNRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345817-off-wall-street-negative-on-monro\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Off Wall Street negative on Monro</a></h4><ul> <li>Off Wall Street says the turnaround plan at Monro (<a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a> <font color='red'>-3.9%</font>) might not be successful due to serious headwinds blowing in against the company.</li> <li>The boutique firm <a href=\"http://www.offwallstreet.com/\" target=\"_blank\">warns</a>&nbsp;in particular on discounting pressure in the tire sector.</li> <li>Off Wall Street initiates coverage on Monro as a short play and sets a price target of $35.25 (36% downside represented).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3345817\" data-linked=\"Off Wall Street negative on Monro\" data-tweet=\"$MNRO - Off Wall Street negative on Monro https://seekingalpha.com/news/3345817-off-wall-street-negative-on-monro?source=tweet\" data-url=\"https://seekingalpha.com/news/3345817-off-wall-street-negative-on-monro\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345814\" data-ts=\"1523888491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHR\" target=\"_blank\">BHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345814-hotel-reits-in-green-after-upped-offer-for-lasalle-hotel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hotel REITs in the green after upped offer for LaSalle Hotel</a></h4><ul><li>Pebblebrook Hotel this morning <a href=\"https://seekingalpha.com/news/3345728-pebblebrook-boosts-bid-lasalle-hotel\" target=\"_blank\">raised its mostly-stock bid</a> for LaSalle Hotel from $30 per share to $31.75. LaSalle is&nbsp;<font color='green'>higher by 2.8%</font>&nbsp;to $30.79.</li><li>The M&amp;A animal spirits is lifting the whole sector: Ashford Prime (AHP <font color='green'>+0.7%</font>), Ashford Trust (<a href='https://seekingalpha.com/symbol/AHT' title='Ashford Hospitality Trust, Inc.'>AHT</a> <font color='green'>+1.6%</font>), Chesapeake Lodging (<a href='https://seekingalpha.com/symbol/CHSP' title='Chesapeake Lodging Trust'>CHSP</a> <font color='green'>+1.1%</font>), Chatham Lodging (<a href='https://seekingalpha.com/symbol/CLDT' title='Chatham Lodging Trust'>CLDT</a> <font color='green'>+0.7%</font>), Host Hotels (<a href='https://seekingalpha.com/symbol/HST' title='Host Hotels & Resorts, Inc.'>HST</a> <font color='green'>+0.9%</font>), Hersha Hospitality (<a href='https://seekingalpha.com/symbol/HT' title='Hersha Hospitality Trust'>HT</a> <font color='green'>+0.8%</font>), Sunstone Hotel (<a href='https://seekingalpha.com/symbol/SHO' title='Sunstone Hotel Investors, Inc.'>SHO</a> <font color='green'>+0.6%</font>), Park Hotels (<a href='https://seekingalpha.com/symbol/PK' title='Park Hotels & Resorts Inc.'>PK</a> <font color='green'>+0.6%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3345814\" data-linked=\"Hotel REITs in the green after upped offer for LaSalle Hotel\" data-tweet=\"$BHR $BHR $AHT - Hotel REITs in the green after upped offer for LaSalle Hotel https://seekingalpha.com/news/3345814-hotel-reits-in-green-after-upped-offer-for-lasalle-hotel?source=tweet\" data-url=\"https://seekingalpha.com/news/3345814-hotel-reits-in-green-after-upped-offer-for-lasalle-hotel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345792\" data-ts=\"1523887903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345792-aptose-bios-cg806-shows-encouraging-action-in-preclinical-studies-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptose Bio&#39;s CG&#39;806 shows encouraging action in preclinical studies; shares ahead 6%</a></h4><ul><li>Aptose Biosciences (<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+6.1%</font>) is up in early trade on the heels of its <a href=\"https://seekingalpha.com/pr/17129828-aptose-presents-new-preclinical-data-cg-806-pan-flt3-pan-btk-inhibitor-2018-aacr-annual\" target=\"_blank\">announcement </a>of encouraging preclinical data on pan-FLT3/pan-BTK inhibitor CG'806 in certain blood cancers. The results were presented at the American Association for Cancer Research Annual Meeting in Chicago.</li><li>According to company scientists, CG'806 was 10x more potent than Daiichi Sankyo's <a href=\"https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006529.html\" target=\"_blank\">quizartinib&nbsp;</a>and as much as 6,000x more potent than AbbVie's (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='green'>+1.1%</font>) Imbruvica (ibrutinib).</li><li>The company is partnering with CrystalGenomics on development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345792\" data-linked=\"Aptose Bio&#39;s CG&#39;806 shows encouraging action in preclinical studies; shares ahead 6%\" data-tweet=\"$APTO $APTO $ABBV - Aptose Bio&#39;s CG&#39;806 shows encouraging action in preclinical studies; shares ahead 6% https://seekingalpha.com/news/3345792-aptose-bios-cg806-shows-encouraging-action-in-preclinical-studies-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3345792-aptose-bios-cg806-shows-encouraging-action-in-preclinical-studies-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345795\" data-ts=\"1523887111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345795-bristol-myers-opdivo-yervoy-combo-beats-chemo-in-first-line-lung-cancer-shares-down-5-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers&#39; Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytruda data</a></h4><ul><li>Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-5.3%</font>) appears to be on the short end of its toe-to-toe <a href=\"https://seekingalpha.com/pr/17130217-opdivo-plus-low-dose-yervoy-combination-reduces-risk-progression-death-42-percent-versus\" target=\"_blank\">data presentation</a> with Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+2.9%</font>) in melanoma at the AACR Annual Meeting in Chicago.</li><li>Results from the Phase 3 CheckMate-227 study showed treatment with the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in first-line advanced non-small cell lung cancer &#40;NSCLC&#41; significantly increased the progression-free survival rate compared to chemo (43% vs. 13%) in patients with high tumor mutational burden &#40;TMB&#41;.</li><li>The overall response rate in the O/Y group was 45.3% compared to 26.9% for chemo. Overall survival, although preliminary, was also favorably impacted by the O/Y combination.</li><li>Merck's data showed the efficacy of KEYTRUDA + chemo regardless of PD-1 status TMB burden.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345719-mercks-keytruda-shows-treatment-benefit-late-stage-study-advanced-melanoma-shares-1-percent\" target=\"_blank\">Merck's Keytruda shows treatment benefit in late-stage study in advanced melanoma; shares up 1% premarket</a> (April 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345795\" data-linked=\"Bristol-Myers&#39; Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytruda data\" data-tweet=\"$BMY $BMY $MRK - Bristol-Myers&#39; Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytruda data https://seekingalpha.com/news/3345795-bristol-myers-opdivo-yervoy-combo-beats-chemo-in-first-line-lung-cancer-shares-down-5-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3345795-bristol-myers-opdivo-yervoy-combo-beats-chemo-in-first-line-lung-cancer-shares-down-5-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345799\" data-ts=\"1523886762\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345799-oracle-expects-cloud-acceleration-announces-fireeye-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle expects cloud acceleration, announces FireEye collaboration</a></h4><ul><li>        Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) co-CEO Safra Catz <a href=\"https://www.reuters.com/article/us-oracle-cloud-growth/oracle-co-ceo-catz-expects-acceleration-in-cloud-business-idUSKBN1HN10G?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">expects</a> the company&rsquo;s cloud business to accelerate following last month&rsquo;s report of cloud sales that missed estimates.</li><li>               Catz blamed the miss on a new model implemented three quarters ago that led to higher license growth, which meant the &ldquo;money is actually coming into another bucket.&rdquo;&nbsp;</li><li>               In other Oracle news, the company and FireEye (NASDAQ:<a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a>) <a href=\"https://seekingalpha.com/pr/17129880-fireeye-oracle-collaborate-cloud-transformation\" target=\"_blank\">announce a collaboration</a> that will bring FireEye Email Security to the Oracle Cloud Marketplace.&nbsp;</li><li>               FireEye Email Security, which runs on Oracle Cloud, is also available through the Oracle Cloud Jump Start demo lab.&nbsp;</li><li>               Oracle shares are&nbsp;<font color='red'>down 0.9%</font>&nbsp;to $45.67.&nbsp;</li><li>               FireEye shares are&nbsp;<font color='green'>up 0.4%</font>&nbsp;to $18.78.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3343737-bloomberg-oracle-ceo-complained-trump-amazon-updated\" target=\"_blank\">Bloomberg: Oracle CEO complained to Trump about Amazon (updated)</a> (April 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345615-bloomberg-oracle-leads-anti-amazon-lobby-pentagon-contract-bid\" target=\"_blank\">Bloomberg: Oracle leads anti-Amazon lobby in Pentagon contract bid</a> (April 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345735-oracle-ceo-admits-cloud-contract-discussion-trump\" target=\"_blank\">Oracle CEO admits to cloud contract discussion with Trump</a> (April 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345799\" data-linked=\"Oracle expects cloud acceleration, announces FireEye collaboration\" data-tweet=\"$ORCL $ORCL $FEYE - Oracle expects cloud acceleration, announces FireEye collaboration https://seekingalpha.com/news/3345799-oracle-expects-cloud-acceleration-announces-fireeye-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3345799-oracle-expects-cloud-acceleration-announces-fireeye-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345798\" data-ts=\"1523886562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIR\" target=\"_blank\">AIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345798-aar-lower-after-60-minutes-mention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAR lower after 60 Minutes mention</a></h4><ul> <li>Shares of AAR Corporation (NYSE:<a href='https://seekingalpha.com/symbol/AIR' title='AAR Corporation'>AIR</a>) are&nbsp;<font color='red'>down 2.98%</font>&nbsp;after the company was mentioned several times in a negative fashion during a <a href=\"https://www.cbsnews.com/news/allegiant-air-the-budget-airline-flying-under-the-radar/\" target=\"_blank\">60 Minutes report</a> on maintenance issues at Allegiant Travel.</li> <li>AAR has a repair contract with Allegiant.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345724-allegiant-travel-falls-damaging-60-minutes-report\" target=\"_blank\">Allegiant Travel falls after damaging 60 Minutes report</a> (April 16)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3345798\" data-linked=\"AAR lower after 60 Minutes mention\" data-tweet=\"$AIR - AAR lower after 60 Minutes mention https://seekingalpha.com/news/3345798-aar-lower-after-60-minutes-mention?source=tweet\" data-url=\"https://seekingalpha.com/news/3345798-aar-lower-after-60-minutes-mention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345797\" data-ts=\"1523886308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VAC\" target=\"_blank\">VAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345797-marriott-vacations-seen-lead-bidder-for-ilg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marriott Vacations seen as lead bidder for ILG</a></h4><ul> <li>Marriott Vacations (<a href='https://seekingalpha.com/symbol/VAC' title='Marriott Vacations Worldwide Corp.'>VAC</a> <font color='green'>+2.6%</font>) is in the pole position to acquire ILG (<a href='https://seekingalpha.com/symbol/ILG' title='ILG, Inc'>ILG</a> <font color='green'>+3.8%</font>), reports Reuters.</li><li>Sources say the offer from Marriott Vacations is the best that ILG has on the table</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3340844-reuters-ilg-explores-merger-apollos-diamond-resorts\" target=\"_blank\">Reuters: ILG explores merger with Apollo's Diamond Resorts</a> (March 21)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3345797\" data-linked=\"Marriott Vacations seen as lead bidder for ILG\" data-tweet=\"$VAC $VAC $ILG - Marriott Vacations seen as lead bidder for ILG https://seekingalpha.com/news/3345797-marriott-vacations-seen-lead-bidder-for-ilg?source=tweet\" data-url=\"https://seekingalpha.com/news/3345797-marriott-vacations-seen-lead-bidder-for-ilg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345794\" data-ts=\"1523886262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345794-trovagene-presents-data-aacr-2018-showing-synergy-of-pcmminus-075-in-combination-flt3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene presents data at AACR 2018 showing synergy of PCM-075 in combination with FLT3 inhibitors in AML; shares up 8%</a></h4><ul><li>Trovagene (<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='green'>+7.7%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/17130186-trovagene-presents-data-aacr-meeting-2018-showing-synergy-pcmminus-075-combination-flt3\" target=\"_blank\">presents</a> data showing that PCM-075 exhibits synergistic activity when combined with FLT3 inhibitors in a human xenograft acute myeloid leukemia &#40;AML&#41; model, at the American Association for Cancer Research &#40;AACR&#41; Annual Meeting in Chicago, IL.</li>                  <li>The poster entitled Selective Polo-like Kinase 1 (PLK1) Inhibitor PCM-075 presents data demonstrating that PCM-075 in combination with quizartinib (Daiichi-Sankyo) resulted in 97.3% tumor growth inhibition, compared to 77.9% with quizartinib and 80.2% with PCM-075 as monotherapy.</li> <li>Additionally, in other in vitro data presented, PCM-075 was found to have synergistic effects when combined with therapies used routinely in many hematologic and solid tumor cancers, including paclitaxel, sorafenib, doxorubicin and cytarabine.</li>   <li>PCM-075 is a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in multiple hematologic and solid tumor cancers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345794\" data-linked=\"Trovagene presents data at AACR 2018 showing synergy of PCM-075 in combination with FLT3 inhibitors in AML; shares up 8%\" data-tweet=\"$TROV - Trovagene presents data at AACR 2018 showing synergy of PCM-075 in combination with FLT3 inhibitors in AML; shares up 8% https://seekingalpha.com/news/3345794-trovagene-presents-data-aacr-2018-showing-synergy-of-pcmminus-075-in-combination-flt3?source=tweet\" data-url=\"https://seekingalpha.com/news/3345794-trovagene-presents-data-aacr-2018-showing-synergy-of-pcmminus-075-in-combination-flt3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345796\" data-ts=\"1523886223\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345796-seven-stars-cloud-sets-listing-deal-on-singapore-blockchain-exchange\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Cloud sets listing deal on Singapore blockchain exchange</a></h4><ul>   <li>Seven Stars Cloud (<a href=\"http://seekingalpha.com/symbol/SSC\" target=\"_blank\">SSC</a> <font color='green'>+5.2%</font>) has set new <a href=\"https://seekingalpha.com/pr/17130225-seven-stars-cloud-announces-listing-agreement-new-singapore-based-blockchain-digital-asset\" target=\"_blank\">digital asset listing/service agreements</a> with Bitlim, a Singapore-based blockchain digital asset exchange.</li>    <li>That will provide for listing, quotations, trading and settlement of SSC's digital index products, the company says.</li>    <li>SSC, with fortunes now tied heavily to blockchain/Bitcoin, is <font color='red'>down 37.1%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345796\" data-linked=\"Seven Stars Cloud sets listing deal on Singapore blockchain exchange\" data-tweet=\"$SSC-OLD - Seven Stars Cloud sets listing deal on Singapore blockchain exchange https://seekingalpha.com/news/3345796-seven-stars-cloud-sets-listing-deal-on-singapore-blockchain-exchange?source=tweet\" data-url=\"https://seekingalpha.com/news/3345796-seven-stars-cloud-sets-listing-deal-on-singapore-blockchain-exchange\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345793\" data-ts=\"1523886097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UFI\" target=\"_blank\">UFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345793-unifiminus-6-on-preliminary-fq3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unifi -6% on preliminary FQ3 results</a></h4><ul><li>Unifi (NYSE:<a href='https://seekingalpha.com/symbol/UFI' title='Unifi Inc'>UFI</a>) <font color='red'>-6%</font> in early trade after <a href=\"https://seekingalpha.com/pr/17129734-unifi-provides-preliminary-third-quarter-business-update\" target=\"_blank\">providing</a> preliminary financial results for FQ3.</li><li>The company expects a net loss of between ($0.4M)-$0.4M, resulting in a diluted EPS loss of between ($0.02) and $0.02.</li><li>\"We anticipated that raw material costs and a challenging domestic landscape would pressure third quarter gross margins, but the operating environment proved even more difficult,\" said CEO Kevin Hall.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345793\" data-linked=\"Unifi -6% on preliminary FQ3 results\" data-tweet=\"$UFI - Unifi -6% on preliminary FQ3 results https://seekingalpha.com/news/3345793-unifiminus-6-on-preliminary-fq3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3345793-unifiminus-6-on-preliminary-fq3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345789\" data-ts=\"1523885636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZTCOF\" target=\"_blank\">ZTCOF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345789-optical-networkers-slide-amid-ban-on-selling-to-zte\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Optical networkers slide amid ban on selling to ZTE</a></h4><ul>     <li>The Commerce Dept. is banning American firms from selling components to China's ZTE (<a href='https://seekingalpha.com/symbol/ZTCOF' title='Zte Corp.'>OTCPK:ZTCOF</a>) for seven years for <a href=\"https://www.reuters.com/article/us-china-zte-exclusive/u-s-bans-american-companies-from-selling-to-chinas-zte-idUSKBN1HN1P1\" target=\"_blank\">violating terms in a sanctions violation case</a>, and related optical equipment makers are sliding.</li>     <li>American companies provide 25-30% of the components used in the telecom equipment that ZTE makes, including networking gear and smartphones.</li>     <li>Acacia (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) has <font color='red'>tumbled 24.3%</font> at the open; Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>) is <font color='red'>down 14.8%</font>.</li>   <li><a href=\"https://seekingalpha.com/news/3252891-zte-enters-guilty-plea-settlement-ranges-1_2b\" target=\"_blank\">ZTE had pleaded guilty</a> to conspiring to violate U.S. sanctions via illegal shipments to Iran, and paid $890M in fines (and faced an additional penalty of $300M).</li>    <li>While the company admitted it had fired four senior employees, it had not disciplined or reduced bonuses to 35 others as it had been directed in the agreement.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345789\" data-linked=\"Optical networkers slide amid ban on selling to ZTE\" data-tweet=\"$ZTCOF $ZTCOF $ACIA - Optical networkers slide amid ban on selling to ZTE https://seekingalpha.com/news/3345789-optical-networkers-slide-amid-ban-on-selling-to-zte?source=tweet\" data-url=\"https://seekingalpha.com/news/3345789-optical-networkers-slide-amid-ban-on-selling-to-zte\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345785\" data-ts=\"1523885249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345785-pareteumplus-3_9-chairmans-letter-guides-to-50-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +3.9% as chairman&#39;s letter guides to 50% revenue growth</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 3.9%</font> premarket after a <a href=\"https://seekingalpha.com/pr/17130079-pareteum-issues-chairmans-update-letter\" target=\"_blank\">chairman's update letter</a> from Hal Turner highlighting business progress.</li>    <li>As of Q1's end, the company's 36-month backlog is at $200M, Turner says, and backlog conversions sped up after the company announced go-live deployments in Europe, South America, North America and Asia Pacific.</li>    <li>The company's announced guidance (for its first time since becoming Pareteum) for full-year revenue growth of at least 50% Y/Y; continued improvement in operating cash flow and EBITDA; target gross margins of 70-75% and improving operating margins into the range of 15-20% over a couple of years; and affirmed expectations for positive EBITDA from continuing operations.</li>    <li>The balance sheet is still strong at more than $15.5M in cash, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345785\" data-linked=\"Pareteum +3.9% as chairman&#39;s letter guides to 50% revenue growth\" data-tweet=\"$TEUM - Pareteum +3.9% as chairman&#39;s letter guides to 50% revenue growth https://seekingalpha.com/news/3345785-pareteumplus-3_9-chairmans-letter-guides-to-50-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3345785-pareteumplus-3_9-chairmans-letter-guides-to-50-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345783\" data-ts=\"1523885123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345783-newlink-down-8-after-bailing-on-indoximod-in-melanoma-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink down 8% after bailing on indoximod in melanoma study</a></h4><ul><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <a href=\"https://seekingalpha.com/pr/17129555-newlink-genetics-announces-initial-phase-1-data-indoximod-plus-radiation-chemotherapy\" target=\"_blank\">announces </a>that it will not proceed to the randomization portion of its Phase 1/2 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02073123?intr=indoximod&amp;spons=newlink&amp;rank=2\" target=\"_blank\">Indigo301</a>, assessing lead candidate IDO-inhibitor indoximod, combined with Merck's KEYTRUDA (pembrolizumab) or Bristol-Myers Squibb's Opdivo (nivolumab) in patients with advanced melanoma. The company's decision was heavily influenced by the recent failure of Incyte's IDO-inhibitor epacadostat in melanoma.</li><li>Shares are down&nbsp;<font color='red'>8%</font>&nbsp;premarket as the company's release of positive data on indoximod in children with brain cancer failed to overcome the impact of bailing in melanoma.</li><li>In the dose-escalation portion of a Phase 1 study in heavily pretreated pediatric patients with progressive brain tumors, treatment with indoximod, in combination with chemotherapy and radiotherapy, median progression-free was 6.2 months and median time to regiment failure was 11.7 months.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3344107-incytes-epacadostat-flunks-late-stage-melanoma-study\" target=\"_blank\">Incyte's epacadostat flunks late-stage melanoma study</a> (April 6)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3344232-newlink-minus-44-percent-sets-review-clinical-programs\" target=\"_blank\">NewLink -44%; sets review of clinical programs</a> (April 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345783\" data-linked=\"NewLink down 8% after bailing on indoximod in melanoma study\" data-tweet=\"$NLNK - NewLink down 8% after bailing on indoximod in melanoma study https://seekingalpha.com/news/3345783-newlink-down-8-after-bailing-on-indoximod-in-melanoma-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3345783-newlink-down-8-after-bailing-on-indoximod-in-melanoma-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345782\" data-ts=\"1523885075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPX\" target=\"_blank\">TPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345782-tempur-sealy-lower-after-loop-capital-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tempur Sealy lower after Loop Capital warning</a></h4><ul> <li>Loop Capital lowers Tempur Sealy (NYSE:<a href='https://seekingalpha.com/symbol/TPX' title='Tempur Sealy International Inc.'>TPX</a>) to a <a href=\"https://www.cnbc.com/2018/04/16/stocks-making-the-biggest-moves-premarket-bac-wpp-iep-mcd-ge-sbux-more.html?__source=newsletter|breakingnews\" target=\"_blank\">Sell rating</a> on a brutal assessment of the retailer that relies on channel checks with vendors. Tempur continues to suffer from the end of its Mattress Firm selling partnership, notes the Loop analyst team.</li> <li>Shares of TPX are <font color='red'>down 2.66%</font> in premarket action, and are now 37% below their 52-week high.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3345782\" data-linked=\"Tempur Sealy lower after Loop Capital warning\" data-tweet=\"$TPX - Tempur Sealy lower after Loop Capital warning https://seekingalpha.com/news/3345782-tempur-sealy-lower-after-loop-capital-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3345782-tempur-sealy-lower-after-loop-capital-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345778\" data-ts=\"1523884620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345778-premarket-gainers-of-9-05-04-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (04/16/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+13%</font>&nbsp;as investors bullish</a> on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma.</li>     <li><a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color='green'>+14%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3345722-fda-accepts-alkermes-marketing-application-alks-5461-mdd-action-date-january-31-2019-shares\" target=\"_blank\">accepts</a> Alkermes' marketing application for ALKS 5461 for MDD.</li>     <li><a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a> <font color='green'>+13%</font>&nbsp;on Tropicana <a href=\"https://seekingalpha.com/news/3345720-eldorado-updates-tropicana-deal\" target=\"_blank\">deal</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3345738-acelrx-completes-human-factors-study-dsuvia-plans-resubmit-nda-q2\" target=\"_blank\">completing</a> the human factors study for DSUVIA.</li>     <li><a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='green'>+6%</font>&nbsp;as Regalia has been <a href=\"https://seekingalpha.com/pr/17130044-regalia-cg-biofungicide-cleared-use-cannabis-colorado-oregon-washington-nevada-departments\" target=\"_blank\">approved</a> for use on cannabis.</li>     <li><a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+7%</font>&nbsp;as Volkswagen considers full <a href=\"https://seekingalpha.com/news/3345763-volkswagen-considers-full-takeover-navistar\" target=\"_blank\">takeover</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+5%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345778\" data-linked=\"Premarket Gainers as of 9:05 am (04/16/2018)\" data-tweet=\"$DVAX $DVAX $ALKS - Premarket Gainers as of 9:05 am (04/16/2018) https://seekingalpha.com/news/3345778-premarket-gainers-of-9-05-04-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345778-premarket-gainers-of-9-05-04-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345776\" data-ts=\"1523884438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDX\" target=\"_blank\">CLDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345776-premarket-losers-of-9-05-4-16-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (4/16/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a>&nbsp;<font color='red'>-47%</font>&nbsp;on METRIC study&nbsp;<a href=\"https://seekingalpha.com/news/3345752-celldexs-lead-candidate-flunks-breast-cancer-study-shares-51-percent-premarket\" target=\"_blank\">failing</a> to meet primary endpoint.</li><li><a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='red'>-21%</font>.</li><li><a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>&nbsp;<font color='red'>-9%</font>&nbsp;on&nbsp;early-stage <a href=\"https://seekingalpha.com/news/3345768-blueprint-medicine-9-percent-premarket-early-stage-bluminus-667-data\" target=\"_blank\">BLU-667</a> data.</li><li><a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17129555-newlink-genetics-announces-initial-phase-1-data-indoximod-plus-radiation-chemotherapy\" target=\"_blank\">announcing</a> Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with DIPG.</li><li><a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/NOV' title='National Oilwell Varco, Inc.'>NOV</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3345733-national-oilwell-varco-expects-q1-revenue-miss\" target=\"_blank\">providing</a> operational update for Q1 2018.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3345776\" data-linked=\"Premarket Losers as of 9:05 am (4/16/2018)\" data-tweet=\"$CLDX $CLDX $ACIA - Premarket Losers as of 9:05 am (4/16/2018) https://seekingalpha.com/news/3345776-premarket-losers-of-9-05-4-16-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3345776-premarket-losers-of-9-05-4-16-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345775\" data-ts=\"1523884029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345775-loxo-up-6-premarket-improved-outlook-for-loxominus-292-after-blueprint-data-on-bluminus-667\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loxo up 6% premarket improved outlook for LOXO-292 after Blueprint data on BLU-667</a></h4><ul><li>Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) perks up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume in apparent reaction to early-stage data from competitor Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) on RET-inhibitor BLU-667.</li><li>Investors apparently perceive rosier prospects for LOXO-292, also a RET inhibitor. Preliminary data will be presented at ASCO in early June.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345768-blueprint-medicine-9-percent-premarket-early-stage-bluminus-667-data\" target=\"_blank\">Blueprint Medicine down 9% premarket on early-stage BLU-667 data</a> (April 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295159-loxo-15-percent-ahead-data-presentation-ret-inhibitor-loxominus-292\" target=\"_blank\">Loxo up 15% ahead of data presentation on RET inhibitor LOXO-292</a> (Sept. 13, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345775\" data-linked=\"Loxo up 6% premarket improved outlook for LOXO-292 after Blueprint data on BLU-667\" data-tweet=\"$LOXO $LOXO $BPMC - Loxo up 6% premarket improved outlook for LOXO-292 after Blueprint data on BLU-667 https://seekingalpha.com/news/3345775-loxo-up-6-premarket-improved-outlook-for-loxominus-292-after-blueprint-data-on-bluminus-667?source=tweet\" data-url=\"https://seekingalpha.com/news/3345775-loxo-up-6-premarket-improved-outlook-for-loxominus-292-after-blueprint-data-on-bluminus-667\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345772\" data-ts=\"1523883946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CROX\" target=\"_blank\">CROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345772-crocs-heads-lower-after-susquehanna-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crocs heads lower after Susquehanna warning</a></h4><ul> <li>Shares of Crocs (NASDAQ:<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a>) are lower in early trading after Susquehanna analyst Sam Poser loses some faith in the retailer due to valuation.</li> <li>\"CROX's current stock price reflects much more future progress that is realistic,\" warns Poser.</li><li>Poser and team <a href=\"https://www.marketwatch.com/story/crocss-stock-drops-after-susquehanna-turns-negative-2018-04-16\" target=\"_blank\">drop</a> Crocs to a Negative rating and keep the price target at $12 (-26% from Friday's close).</li> <li>CROX <font color='red'>-4.73%</font> premarket to $15.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3345772\" data-linked=\"Crocs heads lower after Susquehanna warning\" data-tweet=\"$CROX - Crocs heads lower after Susquehanna warning https://seekingalpha.com/news/3345772-crocs-heads-lower-after-susquehanna-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3345772-crocs-heads-lower-after-susquehanna-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345768\" data-ts=\"1523883450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345768-blueprint-medicine-down-9-premarket-on-early-stage-bluminus-667-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint Medicine down 9% premarket on early-stage BLU-667 data</a></h4><ul><li>Investors appear disappointed with Phase 1 data on Blueprint Medicines' (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) BLU-667 in RET-altered solid tumors. Shares are down&nbsp;<font color='red'>9%</font>&nbsp;premarket, albeit on light volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17129543-blueprint-medicines-announces-proof-concept-data-highly-selective-ret-inhibitor-bluminus-667\" target=\"_blank\">announcement </a>of the results, to be presented today at the American Association for Cancer Research Annual Meeting in Chicago.</li><li>Data from the dose-escalation portion of the Phase 1 study, called ARROW, showed treatment with once-daily BLU-667 reduced tumors in 84% of patients with RET-altered cancer with measurable target lesions.</li><li>The preliminary overall response rates &#40;ORR&#41; in patients with non-small cell lung cancer &#40;NSCLC&#41; and medullary thyroid cancer &#40;MTC&#41; were 50% and 40%, respectively. Across all evaluable patients, ORR was 45%.</li><li>On the safety front, BLU-667 was well-tolerated with most adverse events (AEs) being mild or moderate. Grade 3 (serious) AEs occurring in two or more patients were hypertension and neutropenia. One patient died due to causes unrelated to treatment.</li><li>BLU-667 is an orally available selective inhibitor of a proto-oncogene called RET (rearranged during transfection) which plays a key role in the progression of a range of cancers including NSCLC and MTC.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252316-enrollment-underway-blueprints-early-stage-study-cancer-candidate-bluminus-667\" target=\"_blank\">Enrollment underway in Blueprint's early-stage study of cancer candidate BLU-667</a> (March 20, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3345768\" data-linked=\"Blueprint Medicine down 9% premarket on early-stage BLU-667 data\" data-tweet=\"$BPMC - Blueprint Medicine down 9% premarket on early-stage BLU-667 data https://seekingalpha.com/news/3345768-blueprint-medicine-down-9-premarket-on-early-stage-bluminus-667-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3345768-blueprint-medicine-down-9-premarket-on-early-stage-bluminus-667-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345766\" data-ts=\"1523883348\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345766-schwab-up-1_4-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schwab up 1.4% after earnings beat</a></h4><ul><li>Q1 net income of $783M or $0.55 per share vs. $564M and $0.39 a year ago. Pretax profit margin rises to 41.8% from 40.5%.</li><li>Client assets of $3.31T up 13% Y/Y.</li><li>Helped by the Fed's rate hikes, net interest revenue up 26% to $1.3B, with net interest margin of 2.12% up 25 basis points from a year ago.</li><li>Asset management and administration fees up 3% to $851M. Trading revenue up 5% to $201M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345764-charles-schwab-beats-0_02-beats-revenue\" target=\"_blank\">Charles Schwab beats by $0.02, beats on revenue</a> (April 16)</li><li><a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>&nbsp;<font color='green'>+1.4%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3345766\" data-linked=\"Schwab up 1.4% after earnings beat\" data-tweet=\"$SCHW - Schwab up 1.4% after earnings beat https://seekingalpha.com/news/3345766-schwab-up-1_4-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3345766-schwab-up-1_4-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345761\" data-ts=\"1523882644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVB\" target=\"_blank\">NAVB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345761-navidea-signs-deal-to-sublicense-nav4694-worldwide-development-rights\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navidea signs deal to sublicense NAV4694 worldwide development rights</a></h4><ul> <li>Navidea Biopharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NAVB' title='Navidea Biopharmaceuticals'>NAVB</a>) has <a href=\"https://seekingalpha.com/pr/17129760-navidea-signs-deal-sublicense-nav4694-worldwide-development-rights\" target=\"_blank\">signed</a> a deal to       provide Meilleur Technologies, a wholly owned subsidiary       of Cerveau Technologies, worldwide rights to conduct       research using NAV4694,       as well as an exclusive license for the commercialization of NAV4694 in Australia, Canada, China, and Singapore.</li>     <li>As a result of the agreement, the litigation initiated by Beijing       Sinotau Medical Research Co., will be dismissed.</li>     <li>NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate       intended for use in Positron Emission Tomography imaging and       evaluation of patients with signs or symptoms of cognitive impairment       such as Alzheimer&rsquo;s disease.</li><li>Shares are up&nbsp;<font color='green'>10%</font>&nbsp;premarket.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3345761\" data-linked=\"Navidea signs deal to sublicense NAV4694 worldwide development rights\" data-tweet=\"$NAVB - Navidea signs deal to sublicense NAV4694 worldwide development rights https://seekingalpha.com/news/3345761-navidea-signs-deal-to-sublicense-nav4694-worldwide-development-rights?source=tweet\" data-url=\"https://seekingalpha.com/news/3345761-navidea-signs-deal-to-sublicense-nav4694-worldwide-development-rights\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345762\" data-ts=\"1523882636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNIT-OLD\" target=\"_blank\">CNIT-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345762-cnitplus-3_5-on-new-ad-terminal-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNIT +3.5% on new ad terminal contract</a></h4><ul><li>        China Information Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CNIT-OLD' title='China Information Technology'>CNIT-OLD</a>) <a href=\"https://seekingalpha.com/pr/17129952-cnit-receives-follow-1_6-million-cloud-based-ad-terminal-order-anhui-taoping-34th-member\" target=\"_blank\">enters</a> into a contract to sell 5K CNIT cloud-based elevator ad terminals in office and residential buildings in the Anhui province.</li><li>               The contract was signed with Anhui Taoping Culture and Media. CNIT expects the contract to generate $1.6M in sales and service revenue.&nbsp;</li><li>               CNIT shares are&nbsp;<font color='green'>up 3.5%</font>&nbsp;premarket to $1.79.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3345762\" data-linked=\"CNIT +3.5% on new ad terminal contract\" data-tweet=\"$CNIT-OLD - CNIT +3.5% on new ad terminal contract https://seekingalpha.com/news/3345762-cnitplus-3_5-on-new-ad-terminal-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3345762-cnitplus-3_5-on-new-ad-terminal-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345759\" data-ts=\"1523882039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345759-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) upgraded to Overweight with a $170 (38% upside) price target at Morgan Stanley. Shares up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li><li>NeoGenomics (NASDAQ:<a href='https://seekingalpha.com/symbol/NEO' title='NeoGenomics Inc.'>NEO</a>) upgraded to Buy with an $11 (30% upside) price target at BTIG Research. Shares up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li><li>Globus Medical (NYSE:<a href='https://seekingalpha.com/symbol/GMED' title='Globus Medical'>GMED</a>) downgraded to Neutral at BTIG.</li></ul><div class=\"tiny-share-widget\" data-id=\"3345759\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$LOXO $LOXO $NEO - Premarket analyst action - healthcare https://seekingalpha.com/news/3345759-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3345759-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3345753\" data-ts=\"1523881719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3345753-dropbox-target-raised-to-20-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dropbox target raised to 20% upside</a></h4><ul><li>        DA Davidson <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Dropbox+%28DBX%29+PT+Raised+to+%2436+at+DA+Davidson/14056564.html\" target=\"_blank\">reiterates</a> its Buy rating for Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a>) but raises the price target from $22 to $36. &nbsp;</li><li>           The new target represents a 20% upside to Friday&rsquo;s close. </li><li> Dropbox shares are&nbsp;<font color='green'>up 1.6%</font>&nbsp;premarket to $30.50. &nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3345753\" data-linked=\"Dropbox target raised to 20% upside\" data-tweet=\"$DBX - Dropbox target raised to 20% upside https://seekingalpha.com/news/3345753-dropbox-target-raised-to-20-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3345753-dropbox-target-raised-to-20-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}